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“There is no need to be a doctor or scientist 
to wonder why the human body is capable of resisting 
so many harmful agents in the course of everyday life.” 
I. Metschnikow, Russian immunologist, 1908 
 
 
 
 
1. Introduction 
1.1 Immune system 
The immune system is a network of cells, tissues, and organs working together to 
defend biological organisms against foreign substances and microorganisms. The 
human system is divided into different, step-like sections. The two main subgroups are 
the innate, also called the non-specific immune system, and the acquired (or specific) 
system. The acquired immune system developed supplementary to the evolutionarily 
older defence strategy of the innate system and it is still supplemented and controlled by 
the phylogenetically older system.(40) This relationship is also reflected in the activity 
sequence during immune defence: the innate immune system is the first line of response 
against pathogenic agents. It offers a broad and instantaneous protection, also against 
previous unknown pathogens. The specific immune response is deployed in the 
subsequent phase of infection as well as in the formation of an immunological 
memory.(1) However, in contrast to the innate immune response it takes days to develop 
its maximum efficiency, but through the capability of the specific immune system to 
remember and recognize specific pathogens, it reacts faster and stronger in case of 
recurring infections.(40) 
 
1.2 Innate immunity 
The innate immunity is the dominant defensive weapon of multicellular organisms. The 
molecular components are evolutionary conserved and can also be found in fungi, 
plants, and animals.(3,55) Non-self substances and microorganisms are identified with a 
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limited number of germline-encoded pattern-recognition receptors (PRRs). The 
non-specific immune system represents the first instance of host defence and is 
composed of anatomical barriers, humoral factors, and special immune cells. 
 
1.2.1 Anatomical barriers 
During evolution, multifarious barriers were developed to make it difficult for 
pathogens to penetrate the body. The majority of infectious agents and environmental 
toxins are kept away from the host by these physical structures. The epithelial barrier of 
the skin, gastrointestinal, respiratory, as well as of the genitourinary tract separates the 
host from the external environment and forms an impermeable barrier for most of the 
pathogens. Additionally, infectious components are removed by the peristaltic of the 
gastrointestinal tract or the mucociliary apparatus of the lungs. Gastric acid and the 
physiological flora are other examples of how the body is protected from being 
colonized by microorganisms. 
 
1.2.2 Humoral factors 
The humoral defence of the innate immunity is composed of various substances, 
including complement system, lysozyme, the defensins, as well as cytokines. The 
complement system represents a cascade of 30 plasma proteins, which lead for example 
to opsonization and lysis of the pathogen cells. Lysozyme is a bactericidal enzyme, 
found in many secretes such as tears and saliva. Antimicrobial properties as well, are 
part of the polypeptide defensin, which is found for instance in the granules of 
neutrophil granulocytes. The group of cytokines is various; they include for example the 
interleukins. 
 
1.2.3 Cells of the innate immune response 
Natural killer cells, granulocytes, macrophages, and dendritic cells, as well as 
nonprofessional cells such as ﬁbroblasts, epithelial and endothelial cells are numbered 
among the cells of the innate immune system.(55) The leukocytes of the innate immune 
system are able to identify and eliminate pathogens on their own, but they also 
cooperate closely with the acquired immune system. Dendritic cells, macrophages, and 
B lymphocytes are professional antigen-presenting cells. They present antigenic 
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peptides, bound to major histocompatibility complex class II molecules (MHC II), to 
Th cells, which play an important role in the coordination of the adaptive immune 
response. Important strategies in the fight against pathogens are the phagocytosis and 
the respiratory burst. Professional phagocytes are monocytes, macrophages, neutrophil 
granulocytes, dendritic cells, as well as mast cells.(23) Neutrophils and macrophages are 
able to kill engulfed microorganisms through the generation of reactive oxygen species; 
a process called ‘respiratory burst’. 
 
1.3 Granulocytes 
Granulocytes make up around 60 percent of the leukocytes. The nucleus of mature cells 
has a characteristic lobed appearance; therefore, these cells are also called the 
polymorphonuclear leukocytes (PMN). Three different types of granulocytes can be 
distinguished. They are named according to their dyeing characteristics: neutrophil, 
eosinophil, and basophil granulocytes. Neutrophil granulocytes comprise the largest 
population of the three granulocyte types and also the major fraction of all circulating 
immune cells.(56) These phagocytic and highly motile cells are the primary mediators of 
the innate immune response and the first line of defence against invading 
microorganisms.(44) They congregate quickly at the site of infection, not only to 
phagocyte and to digest the pathogen, but also in order to release cytotoxic, 
chemotactic, and inflammatory substances from their intracellular granules and vesicles. 
These mediators control the immediate immune response and attract other cells, 
including macrophages and dendritic cells, which play a significant role in the 
development of a long-term adaptive immunity.(22,42,47,60,64) Eosinophil granulocytes 
become crucial during parasitic infections and inflammatory processes.(13) The large 
granules of the basophil neutrophils contain histamine, heparin, serotonin, and other 
mediators. The typical allergy symptoms are caused by the release of histamine through 
activated basophils. For this reason, basophil granulocytes, along with mast cells, are 
considered to play the most crucial role in allergic diseases.(82) 
 
1.4 Granulopoiesis 
Like all cellular blood components, granulocytes derive from pluripotential 
hematopoietic stem cells in the bone marrow. During the complex process of 
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granulopoiesis, these early blood cell precursors divide, differentiate, and maturate to 
become functionally active granulocytes. Initially, the differentiation of the stem cell 
results in one of two hematopoietic lineages: either a multipotent lymphoid progenitor 
stem cell or a common myeloid progenitor cell. The myeloid progenitor is also called 
CFU-GEMM, which describes a colony forming unit that generates granulocytes, 
erythrocytes, monocytes, or megakaryocytes. CFU-GEMM gives rise to the CFU-GM 
sublineage. In early granulopoiesis, these granulocyte-macrophage progenitors further 
differentiate into granulocyte-colony-forming units, and these in turn lead to 
myeloblasts. The unipotent myeloblasts are the first morphologically distinguishable 
cells of the granulocytic lineage. As a result of their limited potentiality they are now 
fully restricted to the granulocytic cell line.(51) The next of five further development 
stages is the differentiation into promyelocytes. Consequently, three different precursors 
may arise: the neutrophilic, the basophilic or the eosinophilic myelocytes. Subsequent in 
the differentiation sequence are the metamyelocyte, band neutrophil and finally the 
mature granulocyte. The whole hematopoiesis is strictly controlled by cytokines, 
transcription, and growth factors and occurs in close contact to the stromal 
microenvironment of the bone marrow. For example, the cytokine G-CSF (granulocyte 
colony-stimulating factor) is a hormone-like glycoprotein, promoting proliferation and 
maturation. It is produced by monocytes, macrophages, fibroblasts, and endothelial cells 
in response to stimulation with lipopolysaccharides (LPS), Interleukin-1 (IL-1), or 
tumor necrosis factor alpha (TNFα).(51) All sections of the granulopoiesis are associated 
with the synthesis of stage-specific proteins and the granulocytic precursors undergo 
expressional changes and morphologic transformations during these stages. The 
resulting variety of innate immunity proteins is necessary for the highly complex role of 
polymorphonuclear leukocytes in phagocytosis, microbial defence, and the mediation of 
inflammatory processes. 
 
1.5 Neutrophil granulocytes 
1.5.1 Neutrophil granule heterogeneity 
The wealth of the neutrophil proteins is not found freely dispersed through the 
cytoplasm, but is stored in granules and vesicles. Furthermore, their distribution in the 
cytoplasm is not random; you find them well-sorted according to a certain pattern. This 
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is motivated by a reason: not all stored proteins are needed at the same time and not all 
proteins can co-exist in the same granule, for example a precursor protein and its 
activating protease. Thus, each subset of granules has its characteristic protein profile 
and its specific condition of degranulation.(85) The granules are subdivided into primary 
granules (also known as peroxidase-positive or azurophil granules), secondary (or 
specific granules), and tertiary granules (also called gelatinase granules). The 
azurophilic granules contain the most harmful and toxic weapons of the phagocyte: 
serine proteases and peroxidase. The bactericide protein lactoferrin, for instance, is a 
component of the specific granules. Tertiary granules contain gelatinase to facilitate the 
migration through the extracellular matrix. 
Table 1: Assortment of some neutrophil granule proteins.(8) 
Azurophil granules Specific granules Gelatinase granules 
α1-antitrypsin, 
Cathepsins, 
Defensins, 
Elastase, 
Lysozyme, 
Myeloperoxidase, 
Proteinase-3, 
Sialidase 
ß2-microglobulin, 
Collagenase, 
Histaminase, 
Lactoferrin, 
Lysozyme, 
NGAL, 
Sialidase 
 
Acetyltransferase, 
Gelatinase, 
Lysozyme 
 
 
Beside the liberation of proteins, granules and vesicles play an important role in the 
dynamic organisation of the cell membranes. Their endomembranes furnish the plasma 
membrane with important functional proteins, including phagocytosis and adherence 
mediating proteins, as well as receptors for chemoattractants or complement factors. 
The described diversity of granule composition can hardly arise through the process of 
protein targeting alone. However, the specific protein profile of granules can be 
explained if granules are formed continuously during granulopoiesis and concurrently 
filled with the proteins which are synthesised in the particular stage of development (see 
figure 1). This outlined mechanism is referred to as the 'targeting by timing 
hypothesis'.(10,11,30,85) 
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Figure 1: Targeting by timing hypothesis. GPs=Granular proteins. The granules of the 
granulocytes are formed during granulopoiesis and packed with the proteins 
synthesised in the particular stage of maturation. 
 
1.5.2 Secretory vesicles 
Another type of specialized cytoplasmic organelles, beside the described granules, are 
the secretory vesicles. These cellular components contain plasma proteins and are 
formed by endocytosis during the neutrophils' terminal maturation in the bone marrow. 
As a consequence, their importance does not lie in the storage of immunological or 
microbe harming substances. Instead, secretory vesicles store membrane proteins.(78) 
They represent the main source of receptors, and thus, contribute significantly to the 
instant responsiveness of neutrophils. Among the variety of receptors are: pathogen-
recognition receptors, Fc receptors, interferon receptors, a diversity of chemokine 
receptors, and also receptors responsible for the mediation of diapedesis.(10,85) 
 
1.5.3 Control of exocytosis 
Neutrophils are unique in their capacity to mobilize granules from intracellular stores to 
the cell surface as well as fusing them with pathogen containing phagosomes. This 
flexibility enables the neutrophils to adapt rapidly to a changing microenvironment. 
Granules and vesicles are assigned to a hierarchy, according to their different roles 
during the immunity response. The importance of secretory vesicles in the regulation of 
neutrophils' interaction, especially in the early stages of inflammation, is accompanied 
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by a high propensity for degranulation. The propensity of degranulation is determined 
by the density of fusion proteins in the vesicle membrane. The increasing expression of 
those proteins during granulopoiesis entails that the secretory vesicles possess the 
highest and the azurophil granules the lowest quantity of fusion proteins. Accordingly, 
secretory vesicles are most sensitive to several stimuli and can be mobilized completely, 
whereas only a small amount of peroxidase positive granules are exocytosed at site of 
infection, leaving most of them retained ready for the digestion of phagocyted 
microorganisms.(8-10,85) 
 
1.6 Pattern-recognition receptors 
How do the phagocytes identify potential pathogens? Ingeniously, they make use of 
specific microbe components, for instance LPS, a cell wall component of gram-negative 
bacteria, or characteristic RNA/DNA motifs, which are not expressed in the host's 
system. As the structures are often essential for the microbes' survival, they are highly 
conserved and found in a wide group of microorganisms. These conserved and microbe 
specific components are known as microbe-associated-molecular patterns (MAMPs) or 
pathogen-associated molecular patterns (PAMPs). The receptors of the immune cells 
recognizing these motifs are called pathogen-recognition receptors (PRR). They are 
divided into several families, including transmembrane proteins as the Toll-like 
receptors (TLRs) and C-type lectin receptors (CLRs), secreted proteins like mannan 
binding lectin (MBL) as well as cytoplasmic proteins such as the retinoic acid-inducible 
gene (RIG)-I-like receptors (RLRs) and NOD-like receptors (NLRs).(20,84) The 
recognition of microbial components triggers a cascade of cellular signals, which lead to 
the expression of inflammatory mediators. These mediators control the innate immune 
response but also the development of specific immunity cells. 
 
In addition to PAMPS, PRRs can also be activated through DAMPs (damage-associated 
molecular patterns). DAMPS are endogenous danger signals released by damaged or 
stressed cells. They are intracellular (mostly nuclear or cytosolic) proteins and therefore 
hidden under normal physiological conditions. Examples of DAMPs are HMGB1, heat-
shock proteins, or high extracellular concentrations of ATP.(59,71,72,74) The induced 
inflammatory response occurs in the absence of any pathogens and has therefore been 
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named ‘sterile inflammation'. Cell death can therefore be regarded as universal and 
potent trigger of inflammation, being essential for tissue repair and regeneration. 
Similar to the microbe-induced inflammation, sterile inflammation is characterized by 
the recruitment of leukocytes and the production of pro-inflammatory cytokines like 
TNF and interleukin-1.(16,71) 
 
1.6.1 Toll-like receptors 
Among the microbial-sensing receptors, the Toll-like receptors (TLRs) are the best 
studied ones.(83) So far, eleven different TLR are known in humans.(3) These 
transmembrane proteins recognise a wide range of microbial pathogens, including 
bacteria, viruses, fungi, and protozoa.(39) Activated TLRs initiate cellular signal 
transduction pathways, which trigger the activation of transcription factors, especially 
the activation of NF-κB.(21) NF-κB controls the expression of various genes involved in 
inflammation, for example proinflammatory cytokines, immune receptors, and cell 
surface adhesion molecules.(46) Each TLR recognises a distinct set of molecular 
patterns.(55) The Toll-like receptor 4 (TLR4) for instance, which is expressed by 
different types of immune cells including neutrophils and dendritic cells, detects small 
concentrations of LPS in the surrounding medium.(46,55,83) 
 
1.6.2 NOD-like receptors 
Unlike TLRs, which are membrane-bound molecules recognizing microbial components 
in the extracellular milieu or in endosomal compartments, NOD-like receptors (NLRs) 
sense cytosolic PAMPs and DAMPs. NLRs are characterized by C-terminal leucine-rich 
repeats (LRR domain), a central nucleotide-binding and oligomerization domain 
(NOD), and an N-terminal effector domain. The NLRs are divided, according to their 
N-terminal effector domain, into subfamilies. The majority of NLRs have a caspase 
recruitment domain (CARD) or a pyrin (PYD) domain here.(49) These, also named 
death-fold domains, possess the characteristic to form dimers or multimers with other 
members of the same subfamily. The LRR domain has a regulatory function and is 
responsible for sensing activating signals.(69) However, the precise sensing mechanisms 
are unclear, so it is not known, whether NOD proteins recognize pathogen products 
through direct interaction or if some other accessory molecules are required. In any 
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case, activation leads to a conformation change and to a nucleotide exchange on the 
NACHT domain, which is part of the NOD-domain. This structural rearrangement leads 
to an active state and the ability to oligomerize. The assembled protein oligomer is 
termed 'inflammasome'. These complexes serve as a molecular platform to activate NF-
κB transcriptional pathways as well as pro-caspase-1. Active caspase-1 processes 
several precursors of interleukin-1 family cytokines into their biologically active forms. 
Furthermore, the processing of pro-caspase-1 is essential for the regulation of the 
inflammatory form of cell death, the pyroptosis.(12) 
 
1.6.3 NALP3 inflammasome 
The most thoroughly investigated inflammasome is NALP3, also known as cryopyrin. 
NALP3 contains an N-terminal PYD domain and activates pro-caspase-1 indirectly 
through the bridging molecule ASC, which is composed of a PYD and a CARD domain 
(see figure 2). It interacts with NLRP3 via homotypic PYD-PYD interaction and 
recruits on the other side pro-caspase-1 through a CARD-CARD interaction.(52) 
Mutations in the NALP3 gene are linked to a series of hereditary autoinflammatory 
fever syndromes called CAPS (see chapter 1.9). Furthermore, a lot of infectious or 
sterile inflammatory conditions show a NALP3 activation. This is due to the broad 
variety of NALP3 activating substances, including DAMPS, microorganisms, as well as 
exogenous non-microbial substances like urate crystals. For instance, the microbial 
toxin and ionophore nigericin is a potent NALP3 inflammasome activator. This pore-
forming toxin causes a net decrease in the intracellular potassium level in a pannexin-1-
dependent manner. Similar to nigericin, ATP decreases also the intracellular potassium 
concentration. ATP binds to the purinergic receptor P2X7, which leads to the opening of 
ATP-gated cation channels and subsequent to the recruitment of the hemichannel 
protein pannexin-1. Pannexin-1 forms large pores in the cell membrane, through which 
microbial products like LPS can be delivered into the cytoplasm.(3,12) Nevertheless, the 
exact mechanisms of inflammasome activation are still poorly understood. Considering 
the differences in structure and function of the molecules reported to activate NLRP3 
inflammasomes, a direct interaction is hardly probable. It seems, like the stimuli end up 
in a common pathway like the efflux of intracellular potassium. However, it is possible 
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that additional, so far unknown signals of cellular injury contribute to the assembly of 
NLRP3. 
 
Figure 2: Structure of the NALP3 inflammasome. NALP3 is characterised by three 
functional domains, consisting of a C-terminal ligand-sensing leucine-rich repeat (LRR) 
domain, a central oligomerisation domain (NACHT), and an N-terminal pyrin (PYD) 
domain. The NALP3 inflammasome activates pro-caspase-1 through the bridging 
molecule ASC (apoptosis-associated specklike protein containing a caspase-recruitment 
domain (CARD)). ASC interacts with NALP3 via homotypic PYD-PYD interaction and 
recruits on the other side pro-caspase-1 through a CARD-CARD interaction. 
 
1.7 Caspase-1 
Caspase-1 is a member of the cysteine-aspartic acid protease (caspase) family and was 
previously termed interleukin-1ß-converting enzyme (ICE). However, it is not merely 
an ICE, it is also required for the proteolytic processing of pro-IL-18.(67) Like other 
caspases, caspase-1 is in turn synthesised as an inactive zymogen. It becomes 
autoproteolytically active after controlled dimerization through the inflammasomes. 
Beside cytokine activation, caspase-1 is capable of triggering pyroptosis. This form of 
programmed cell death is associated with the release of proinflammatory cellular 
contents and is therefore part of the defence mechanism. 
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1.8 IL-1α, IL-1ß, IL-18, and IL-33 
The IL-1 family contains 11 members, notably IL-1α, IL-1ß, IL-18, and IL-33. These 
cytokines are all produced as inactive zymogens. Consequently, their activity is 
controlled in a posttranscriptional fashion in addition to their transcriptional regulation. 
To what extend the NLRP3/ASC/Caspase-1 axis is involved in their activation is not 
fully understood. In particular, the production mechanisms of those cytokines in 
neutrophil granulocytes are still relatively unclear. 
 
1.8.1 IL-1ß 
The proinflammatory cytokine IL-1ß has important local, but also systemic effects, for 
instance as endogenous pyrogen. It activates endotelium, T cells, and macrophages and 
is therefore an important mediator of the immune response during infection and 
inflammation. IL-1ß is involved in acute and chronic autoimmune diseases, diabetes, 
pain, as well as in neurological disorders like schizophrenia.(19,80) Furthermore, 
abnormal increased IL-1ß levels are a distinctive feature of autoinflammatory diseases. 
Various cell types are capable of releasing IL-1ß; among these are macrophages, 
keratinocytes, fibroblasts, mast cells, glial, as well as neuronal cells.(68,89) IL-1β is 
synthesised as a 33-kDa precursor protein, which lacks biologic activity and requires a 
processing into the mature 18-kDa protein. Pro-IL-1β can be proteolyticaly cleaved as a 
consequence of inflammasome activation and however, alternatively, in a caspase-1-
independent fashion.(29,35,57) Proteases capable of cleaving the pro-IL-1β protein include, 
among others, the neutrophil serine proteases(7,35,37,76), bacterial cysteine proteases(36), 
granzyme A(34), and matrix metalloproteinases (MMPs)(75). 
 
1.8.1.1 Regulation of IL-1ß secretion in PBMCs 
Studies on the structure and function of inflammasomes in PBMCs resulted in a ‘two-hit 
theory’ concerning the secretion of IL-1ß (see figure 3). The reason behind is that the 
IL-1ß production seems to be the outcome of two distinct activating signals, acting 
through two different PRRs: the first signal induces, through a TLR, the transcription of 
pro-IL-1ß. After this 'cell priming', a second hit is required to activate the 
inflammasome, which cleaves the precursor protein into biologically active IL-1ß. 
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Figure 3: Two-hit theory of IL-1ß production in PBMCs. An initial priming step with 
LPS induces via TLR4 the NF-κB transcriptional pathways. The subsequently 
synthesised zymogen pro-IL-1ß is cleaved into its mature form through caspase-1 (C1). 
The second stimulus is required to generate the active form of caspase-1. ATP and 
nigericin induce NALP3 assembly and thereby the generation active caspase-1. 
 
1.8.1.2 Regulation of IL-1ß secretion in neutrophil granulocytes 
Several previous studies provided evidence that neutrophils represent a substantial 
source of IL-1β in vitro and in vivo, both in the murine as well as in the human 
system.(6,14,17,29,35,57) Although the regulation of IL-1ß processing and secretion has been 
thoroughly analysed in macrophages, the precise mode of IL-1ß generation by human 
neutrophils remains only partially understood. Different studies have drawn 
INTRODUCTION 
 
13 
controversial conclusions whether neutrophil derived IL-1ß stems mainly from 
inflammasome- or serine protease-dependent activities. This question is of particular 
relevance, as neutrophil granulocytes store the major source of serine proteases in their 
primary granules.(30,53) Previous studies pointed indeed to caspase-1-independent 
pathways of neutrophil IL-1ß processing: the investigations demonstrated that several 
neutrophil proteases, like proteinase 3 (Prtn3) and neutrophil elastase (Ela2), were able 
to cleave pro-IL-1ß into its biologically active form.(17,37,76) Furthermore, other studies 
indicated an IL-1ß production in caspase-1 deficient mice.(29,35,57) Recent studies refute, 
at least partially, inflammasome independent processing. In 2011, Guarda et al. detected 
NLRP3 expression in neutrophils, even under resting conditions, and the expression was 
highly augmented after exposure to pro-inflammatory stimuli.(28) This induced 
expression could suggest a functional role of NALP3 in activated neutrophils. Mankan 
et al. (2012) isolated neutrophils from prtn3/ela2-, asc-, nalp3-, and caspase-1-
knockout mice and stimulated them according to the two-hit theory of inflammasome 
activation. In this study, no significant difference in the amount of released IL-1ß 
between WT and prtn3/ela2-knockout mice was found. The prtn3ˉ/ela2ˉ neutrophils 
were fully capable of secreting IL-1ß, whereas no IL-1ß was secreted by neutrophils 
from caspase-1, asc-, or nalp3- knockout mice.(48) These findings imply that, at least in 
murine neutrophils, the NALP3/ASC/caspase-1 axis plays an essential role in the IL-1ß 
processing. The opposed data from different studies could argue for different types of 
IL-1ß driven inflammation, in which inflammasome-independent but also 
inflammasome-dependent processes exist. Finally, the contribution of NALP3 
inflammasomes as well as the involvement of Prtn3 and Ela2 in the neutrophil IL-1ß 
production are not conclusively and need to be clarified by further investigations. 
 
1.8.2 IL-1α 
Pro-IL-1α is encoded in the same gene cluster like its close homologue pro-IL-1ß. 
These two members of the IL-1 family are structurally related and share the same cell 
surface receptor, the IL-1R. Through this common receptor, the biological function of 
IL-1ß and IL-1α should in principle be identical to a large extent. However, the 
immunological role of IL-1α is still not well defined and some studies suggest that 
IL-1α is less potent than IL-1ß.(63) The synthesis of pro-IL-1α is induced by Toll-like 
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receptor mediated NF-κB activation.(31) However, the exact factors leading to the 
processed form of IL-1α are not clear. Studies came to different conclusions regarding 
the inflammasome dependency of IL-1α activation. IL-1α was secreted in response to 
NLRP3 inflammasome activators but its secretion was not universally inflammasome 
dependent. Inflammasome-independent activation of IL-1α was observed through the 
calcium-activated protease calpain (CANP).(27,43,90) 
 
1.8.3 IL-18 
Since IL-18 induces an IFNγ production by T cells and NK cells, it was previously 
known as interferon-gamma-inducing factor (IGIF). It is known to be synthesised by a 
variety of cells including macrophages, dendritic cells, keratinocytes, osteoblasts, and 
synovial fibroblasts.(70) Pro-IL-18 is supposed to be constitutively expressed in PBMCs 
as well as in neutrophils. However, in the gene regulation, NF-κB seems to be involved 
as well.(24,50,65,70) As in the case of its related cytokine IL-1ß, IL-18 is synthesised as an 
inactive proenzyme requiring a proteolytic cleavage by caspase-1 to generate the 
bioactive molecule. Moreover, alternative caspase-1 independent mechanisms for IL-18 
processing are discussed. These inflammasome independent pathways could consist of 
extracellular cleavage by neutrophil-derived serine proteases or by proteases released 
from cytotoxic T cells.(86) 
 
1.9 CAPS 
Cryopyrin-associated periodic syndromes (CAPS) are a group of rare hereditary 
inflammatory disorders characterized by recurrent periods of systemic inflammation, 
resulting in fever, rash, elevation of acute phase reactants, and joint pain. The group 
encompasses three, often overlapping, phenotypes varying in severity and the 
involvement of different physiological systems. The familial cold autoinflammatory 
syndrome (FCAS) is the mildest form; the other phenotypes are the Muckle-Wells 
syndrome (MWS) and the neonatal-onset multisystem inflammatory disease (NOMID), 
which represents the most severe form of the CAPS.(79) These monogenetic 
autoinflammatory disorders are often caused by a gain-of-function mutation in the 
NLRP3 gene. The resulting spontaneous activation of NALP3 and overproduction of 
interleukin-1 represent the central pathophysiology.(33,38,61) The IL-1-mediated 
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symptoms flare and can be triggered by cold exposure, stress, or unknown causes. 
Symptom-free intervals are characterised by complete wellbeing and normalisation of 
the acute phase reactants. Due to the fact that IL-1ß plays a pivotal role in the 
pathogenesis, it represents an important therapeutic target. Currently, there are three 
drugs available: the interleukin-1 receptor antagonist Anakinra, the IL-1ß monoclonal 
antibody Canakinumab, and the interleukin-1 trap Rilonacept. The treatment targeting 
IL-1 has shown positive effects on patients’ clinical symptoms and quality of life.(15,45,91) 
 
1.10 Muckle-Wells syndrome 
The Muckle-Wells syndrome (MWS) was first described in 1962 by Thomas Muckle 
and Michael Wells.(54) The autosomal dominant transmitted disorder occurs in a varying 
intra- and interfamilial degree of severity. Its exact prevalence is unknown, but with 
regard to Europe, MWS is listed in the Orphanet database of rare diseases. This 
presupposes that the Muckle-Wells syndrome and its subtypes affect less than 1 per 
2,000 people. The age of MWS onset is variable, but the symptoms usually develop 
during childhood. Although genetic tests are feasible, the diagnosis is predominantly 
based on the clinical signs: MWS is characterized by urticarial or erythematous rashes, 
fever, musculoskeletal symptoms, conjunctivitis, and progressive sensorineural hearing 
loss. The severity resides in the inconstant appearance of a secondary systemic 
AA-amyloidosis. The levels of inflammation parameters are usually elevated in patients 
with MWS, particularly during the acute episodes.(32) 
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2. Aims of this study 
The contribution of neutrophils, as dominant circulating human immune cell, to the 
production of IL-1 family cytokines remains poorly understood. Moreover, the modality 
of the neutrophil cytokine synthesis, processing, and secretion represents a controversial 
issue. Based on these open questions our project was focused in particular on the 
following subjects: 
• To what extend are human neutrophils capable of secreting IL-1ß, IL-1α, IL-33, 
and IL-18? How high are the achieved interleukin concentrations in relation to the 
autologous PBMCs? 
• Do the neutrophils produce cytokines in an inflammasome-dependent or serine 
protease-dependent manner? 
• What are the effects of intrinsic inflammasome activation through CIAS1 mutation 
on the cytokine production? 
• Where is the intracellular localisation of the inflammasome in human neutrophils? 
 
Since traditionally Ficoll density gradient isolated neutrophils are commonly 
contaminated with monocytes(62,73), we utilised negatively selected, highly purified 
neutrophils to assess their quantitative role in the generation of the investigated 
cytokines. 
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3. Materials 
3.1 Chemicals, media, buffers, and reagents  
Product name Company; registered office 
ATPNa2 Sigma Aldrich Chemie; Munich, GER 
Biocoll Separating Solution Biochrom; Berlin, GER 
BSA Carl Roth, Karlsruhe; GER 
Calcium Chloride Sigma-Aldrich Chemie; Munich, GER 
DNase I, RNase free (1 U/µl)  Biozym; Hessisch Oldendorf, GER 
Dulbecco’s PBS (1x) PAA Laboratories; Cölbe, GER 
EDTA Sigma-Aldrich Chemie; Munich, GER 
EGTA Sigma-Aldrich Chemie; Munich, GER 
FCS  Biochrom AG; Berlin, GER 
GlutaMAX Invitrogen; Karlsruhe, GER  
Glycerol Sigma-Aldrich Chemie; Munich, GER 
Heparin-Natrium-25000 Ratiopharm; Ulm, GER 
Hepes Sigma-Aldrich Chemie; Munich, GER 
Human Neutrophil Enrichment Kit STEMCELL; Vancouver, CAN 
Isopropanol Merck; Darmstadt, GER 
Magnesium chloride Sigma-Aldrich Chemie; Munich, GER 
Magnesium phosphate Sigma-Aldrich Chemie; Munich, GER 
Magnesium sulphate heptahydrate Sigma-Aldrich Chemie; Munich, GER 
NGS, heat inactivated R&D Systems; Minneapolis, US 
Penicillin-Streptomycin Invitrogen; Karlsruhe, GER  
Percoll GE Healthcare; Buckinghamshire, UK 
Phenylmethylsulfonyl fluoride Sigma-Aldrich Chemie; Munich, GER 
PIPES Sigma-Aldrich Chemie; Munich, GER 
Potassium chloride Sigma-Aldrich Chemie; Munich, GER 
Potassium dihydrogen phosphate Sigma-Aldrich Chemie; Munich, GER 
Protease Inhibitor Cocktail, Mini Roche; Mannheim, GER 
Roti-Nanoquant Carl Roth; Karlsruhe, GER 
RPMI 1640 medium Biochrom; Berlin, GER 
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Product name Company; registered office 
Sodium bicarbonate  Sigma-Aldrich Chemie; Munich, GER 
Sodium chloride Sigma-Aldrich Chemie; Munich, GER 
Sulphuric acid (2N) Carl Roth, Karlsruhe; GER 
Tween 20 Carl Roth; Karlsruhe, GER 
 
3.2 Western blot 
Product name Company; registered office 
Amersham Hyperfilm GE Healthcare; Buckinghamshire, UK 
ECL GE Healthcare; Buckinghamshire, UK 
iBlot 7-Minute Blotting System Invitrogen; Karlsruhe; GER 
iBlot Gel Transfer Stacks, PVDF Invitrogen; Karlsruhe, GER 
Novex Sharp Pre-stained Standard Invitrogen; Karlsruhe, GER 
NuPage 4 - 12 % Bis-Tris Gel Invitrogen; Karlsruhe, GER 
NuPage Antioxidant Invitrogen; Karlsruhe, GER 
NuPage LDS Sample Buffer Invitrogen; Karlsruhe, GER 
NuPage MES SDS Running Buffer Invitrogen; Karlsruhe, GER 
NuPage Reducing Agent Invitrogen; Karlsruhe, GER 
PowerEase 500 Invitrogen; Karlsruhe; GER 
Slimfast Vanille Allpharm; Messel, GER 
xCell SureLock Electrophoresis cell Invitrogen; Karlsruhe, GER 
 
3.3 Antibodies 
Product name Company; registered office 
Anti NALP3 (mouse, monoclonal) Abcam; Cambridge, UK 
Anti Caspase-1 (rabbit, polyclonal) Abcam; Cambridge, UK 
Rabbit anti Goat, HRP conjugate Millipore; Massachusetts, US 
Goat anti Rabbit, HRP conjugate Dako; Glostrup, DK 
Goat anti Mouse, HRP conjugate Dako; Glostrup, DK 
Anti ß2M (rabbit polyclonal)  Dako; Glostrup, DK 
Anti HLA ABC( mouse, monoclonal) Dako; Glostrup, DK 
Anti MICA (rabbit, polyclonal) Abcam; Cambridge, UK 
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3.4 ELISA 
Product name Company; registered office 
Human Albumin ELISA Kit ICL; Portland, US 
Human Lipocalin-2/NGAL DuoSet R&D Systems; Minneapolis, US 
Human Myeloperoxidase DuoSet R&D Systems; Minneapolis, US 
Human IL-18 ELISA Kit MBL Woburn; US 
Human MMP-9 DuoSet R&D Systems; Minneapolis, US 
Human IL-1 beta/IL-1F2 DuoSet R&D Systems; Minneapolis, US 
Human IL-1α ELISA Set Hologic; Massachusetts, US 
 
3.5 Prepared solutions, buffers, and media 
Solution/Buffer/Medium Composition 
cRPMI RPMI 1640, 
10 % FCS, 
10 mM Penicillin-Streptomycin, 
10 mM GlutaMax 
Disruption buffer (10X) 100 mM KCL, 
3 mM NaCl, 
3,5 mM MgCl2, 
10 mM PIPES, 
0,5 mM PMSF, 
50 mM ATPNa2 
(pH 7,2) 
EasySep recommended medium PBS, 
2 % FCS, 
1 mM EDTA 
ELISA reagent diluent PBS, 
1% BSA 
(0.2 µm filtered) 
ELISA wash buffer PBS, 
0,05 % Tween 20 
Krebs-Ringer solution 115 mM NaCl, 
4,7 mM KCL, 
2,56 mM CaCl2, 
1,2 mM KH2PO4, 
1,2 mM MgSO4 x 7 H2O, 
20 mM NaHCO3, 
16 mM Hepes 
(pH 7,2)  
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Solution/Buffer/Medium Composition 
Lysing buffer 
(Universitäts-Apotheke Tübingen) 
1000 ml H2O, 
8,29 g NH4Cl, 
1 g KHCO3, 
0,0372 g Na2-EDTA-2H2O 
PBS-T PBS, 
0,05 % Tween 20 
Relaxation buffer 100 mM KCL, 
3 mM NaCl, 
3,5 mM MgCl2, 
12,5 mM EGTA, 
10 mM Piperazine 
(pH 7,2) 
Western blot blocking buffer PBS-T, 
3 % Slimfast Vanille 
 
3.6 Stimulants and inhibitors 
Product name Company; registered office 
ATP Sigma Aldrich Chemie; Munich, GER 
LPS Sigma Aldrich Chemie; Munich, GER 
Nigericin sodium salt (5 mg/ml) Sigma Aldrich Chemie; Munich, GER 
PMSF Sigma Aldrich Chemie; Munich, GER 
Z-VAD-FMK Enzo Life Sciences; Lörrach, GER 
 
3.7 Instrumental and electronic equipment 
Product name Company; registered office 
Analytical balances BP121S Sartorius; Göttingen, GER 
Blockthermostat TCR 100 Roth; Karlsruhe, GER 
Centrifuge 5430 R Eppendorf; Hamburg, GER 
Exposure cassette GE Healthcare; Buckinghamshire, UK 
FACS Calibur BD Bioscience; New Jersey, US 
Heraeus Megafuge 16R Thermo Scientific; Massachusetts, US 
Inkubator Hera Cell Thermo Scientific; Massachusetts, US 
Magnetic stirrer Neolab; Heidelberg, GER 
Microscope Olympus IX50 Olympus; Hamburg, GER 
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Product name Company; registered office 
Photometer Victor 1420 PerkinElmer; Rodgau, GER 
Pressure chamber PARR; Illinois, US 
GraphPad Prism 5 Graph Pad Software 
Roller Cat RM 5 Neolab; Heidelberg, GER 
Safety-Multifly Sarstedt; Nümbrecht, GER 
Silver EasySep Magnet STEMCELL; Vancouver, CAN 
Sterile Filter 0,2 µm Merck; Darmstadt, GER 
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4. Methods 
4.1 Isolation of PBMCs and neutrophil granulocytes 
4.1.1 Ficoll-Hypaque density gradient centrifugation  
The density gradient centrifugation is a standard method to segregate different blood 
cells in a gentle and quick way. Therefore, a Ficoll separating solution is used, which 
conventionally contains a synthetic sucrose-epichlorhydrin copolymer with a specific 
density of 1.077 g/ml. The anticoagulated whole blood is carefully layered above the 
Ficoll and is separated during a centrifugation step. The blood cells with a higher 
density than 1.077 g/ml, such as granulocytes and erythrocytes, pass through the Ficoll 
layer and sediment on the bottom. The cells with a lower density cluster in the 
interphase above the Ficoll. These cells are called the peripheral blood mononuclear 
cells (PBMCs). The PBMC group consists of macrophages, monocytes, and 
lymphocytes. Plasma, which has the lowest density of all blood components, can be 
found at the top of all layers, above the PBMC-ring. 
 
For cell isolation, one part of the Ficoll separating solution was given into a conical 
reaction tube and 1.5 parts of undiluted heparinized whole blood was slowly layered 
above. The tube was centrifuged at 400 x g for 35 minutes at 20 °C. To keep the 
components from intermixing, the acceleration and deceleration were turned down. 
 
4.1.2 PBMC and plasma isolation 
After the density gradient centrifugation, one millilitre of the plasma was collected and 
stored at -20 °C. The PBMC-ring was aspirated with a Pasteur pipette and transferred 
into a new tube. In order to remove remaining Ficoll solution, we washed the cells twice 
with RPMI medium. This was important for preventing cell toxic or cell stimulating 
effects of the Ficoll solution, resulting from prolonged cell exposure. The centrifugation 
steps were conducted for 10 minutes at 300 x g. Subsequently, the cells were 
resuspended and the cell count was determined. 
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4.1.3 Isolation of neutrophil granulocytes 
4.1.3.1 Erythrocyte lysis 
After the discharge of the Ficoll plaque the polymorphonuclear cells remained in the 
tube together with the erythrocytes. The erythrocytes were subjected to a cell lysis with 
an ammonium chloride-based reagent. The cells were resuspended with the precooled 
lysing buffer and incubated for 20 minutes at 4 °C. Each incubation was followed by a 
centrifugation step at 400 g for 10 minutes. Subsequently the PMNs could be 
resuspended and the cell count was determined. 
 
4.1.3.2 Immunomagnetic separation of neutrophils with EasySep  
The immunomagnetic cell separation method was used to get highly purified neutrophil 
granulocytes. In particular, we wanted to remove contaminating monocytes, as they 
would have falsified the subsequent experiments. Furthermore, the isolation method 
with EasySep was chosen since it is based on a negative selection. The advantage of a 
negative immunological separation, compared to a positive selection technique, is that 
the required cells are not antibody-labelled. Consequently, the exposure to potential 
activating agents is reduced and the natural behaviour of the cells is less influenced.(18) 
 
The cells were adjusted in the recommended medium to a density of approximately 
50 million cells per millilitre and 50 µL EasySep Enrichment Cocktail per ml cells were 
added. This is an antibody cocktail containing antibodies directed against cell surface 
markers of the unwanted cells: CD2, CD3, CD9, CD19, CD36, CD56, and 
glycophorin A. Thus, contaminating T and B cells, platelets, erythrocytes, monocytes, 
and NK-cells were tagged. Additionally, the Fc region of these antibodies bound 
specifically to dextran. This property was used in the next step, when 100 µl dextran 
encased ferrous particles per ml cells were added. After 10 minutes of incubation, the 
polystyrene tube, containing the tetrameric complexes composed of negative selected 
cell, antibody, dextran, and the ferrous particle, was places in the EasySep magnet. The 
magnetically labelled cells were attracted to the wall of the reaction vessel and held 
there by magnetic attraction. At this stage, the suspension containing the desired and 
still freely movable cells could be poured into a new tube. This separation in the magnet 
was repeated for a second time. Subsequently, we centrifuged the cell suspension at 
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350 x g for 10 minutes and resuspended the purified neutrophil granulocytes in the 
medium required for the next step. 
 
4.1.4 Adjustment of cell densities 
A small aliquot of the cell suspension was further diluted (e.g. 5 µl sample plus 995 µl 
RPMI medium) and 10 µl of this dilution were applied into a Neubauer chamber 
beneath the cover-slip. At least four large squares were counted and the mean value was 
calculated. The cell density was estimated with the following computational function: 
Average count per large square  x  Dilution factor  x  104. 
 
4.2 Subcellular fractionation of neutrophil granulocytes  
(Method originally described by Borregaard, 1999(41)) 
The subcellular fractionation is a pivotal method in the investigation of neutrophils’ 
subcellular organisation and granule composition. The granules (azurophilic/primary, 
specific/secondary, and gelatinase/tertiary), the secretory vesicles, the plasma 
membrane, as well as the cytosol can be separated by this method and the resulting 
single components can be further characterised. We worked with nitrogen cavitation 
followed by a three- and a four-layer Percoll density gradient. All steps were performed 
at 4 °C with precooled buffers and equipment. 
 
4.2.1 Whole blood collection 
500 ml blood was collected from healthy volunteers by antecubital venipuncture after 
informed consent and approval of the study by the ethics committee of the University of 
Tübingen. EDTA was used for anticoagulation. None of the donors had any known 
acute or chronic infections. 
 
4.2.2 Nitrogen cavitation 
For cell lysis we used the nitrogen cavitation method, which is an effective and 
indulgent tool for cell disruption. An important positive aspect is the preservation of the 
granule integrity during the whole process. Previous to the lysis, the highly purified 
neutrophils were suspended in 5 ml isotonic Krebs-Ringer-phosphate solution and 
incubated for 5 minutes. The supernatant was discharged after a 10 minute 
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centrifugation step at 200 x g and the pellet was resuspended in disruption buffer which 
additionally contained a mixture of different protease inhibitors. The resulting cell 
suspension was placed under high nitrogen pressure in an apparatus called 'cell bomb'. 
This pressure was released rapidly after a certain time. Whenever a three-layer Percoll 
density gradient was planned subsequent to nitrogen cavitation, the cells were kept at 
380 psi for 10 minutes in the cell bomb. The cells intended to be used for a four-layer 
gradient were treated for 5 minutes at 600 psi. Different theories exist concerning the 
mechanism leading to the cell lysis: one explanation is that the nitrogen, dissolved in the 
cells' liquid phase under high pressure, bubbles out of solution and this results in cell 
disruption. Another possible explanation is that cell lysis is caused by shear stress 
during the release of the cell suspension through the cell bomb’s outlet nozzle.(8) 
Probably both mechanisms contribute to the cell disruption. After nitrogen cavitation, 
we added EGTA (1.5 mM) to the homogenate to avoid aggregation of granules. Cell 
nuclei and non-disrupted cells were pelletized during a 15 minute centrifugation step at 
400 x g. The resulting post-nuclear supernatant was used for the following fractionation 
on the Percoll density gradients. 
 
4.2.3 Percoll density gradient 
Percoll is a density separating medium, containing silica particles coated with PVP. An 
advantage of Percoll is its low viscosity, resulting in a good gradient stability and 
membrane integrity. Additionally, the osmolarity of Percoll is minimal and no shrinking 
effect of the organelles occurs. Beyond that, it is non-toxic towards cells or their 
constituents.(85) 
 
We generated three- and four-layer gradients by layering progressively less dense 
Percoll solutions upon one another. The different cell components migrate down the 
gradient, until they reach a point where their density matches to that of the Percoll. After 
centrifugation, four distinct bands containing the different subcellular components, were 
visible: the lowest band contained azurophilic granules, followed by bands containing 
the specific granules, the gelatinase granules, the secretory vesicles, and the cytosol (see 
figure 4). The gain of a three-layer gradient was the presence of the cytosol as a single 
fraction. However, the plasma membrane and the secretory vesicles were found in one, 
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assorted fraction in the three-layer gradient. The secretory vesicles were dividable in the 
four-layer gradient, but the cytosol was mixed with the plasma membranes. One 
possibility to acquire every fraction separately is to combine the results of the two 
gradients. In order to simplify the procedure, we tried to separate the cytosol and the 
plasma membrane by measuring the MHC class I chain-related molecule A (MICA) in 
the upper regions of a four-layer gradient by western blot analyses. 
 
 
 
 
 
 
 
  
Three-layer gradient Four-layer gradient 
 
Figure 4: Three- and four-layer Percoll density gradients after centrifugation. The post-
nuclear supernatant of nitrogen-cavitated neutrophils was layered on top of the density 
gradients. The subcellular components resolved into four distinct bands during the 
centrifugation step at 20,000 x g for 40 minutes. The lowermost band contained the 
azurophilic granules, followed by bands containing specific granules, gelatinase 
granules, secretory vesicles, and the cytosol. The three- and the four-layer gradients 
differed only in the localisation of the plasma membranes: within the three-layer 
gradient, the plasma membranes formed one fraction together with the secretory 
vesicles, whereas in the four-layer gradient they were colocalised with the cytosol. 
Therefore, the three-layer gradient was used to characterise cytosolic proteins, while 
the four-layer gradient was applied in order to discriminate secretory vesicle proteins 
from those in the plasma membrane. 
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4.2.3.1 Preparation of the Percoll solutions 
The Percoll stock solution was mixed with 10-fold concentrated relaxing buffer and 
distilled water. The required volume of the Percoll stock solution was calculated using 
the following formula: VP= )1(
)006.1( 00
−
−
PD
DV
. 
VP  = Volume of the Percoll stock solution 
Vo = Final volume of the Percoll solution 
Do = Desired density of the Percoll solution 
DP = Density of the Percoll stock solution 
1.006 = Density of the 10-fold concentrated relaxing buffer in g/ml 
 
4.2.3.2 Three-layer Percoll gradient 
Three different Percoll density solutions, each with a volume of 30 ml and a pH of 7.0, 
were prepared as shown in table 2. Nine millilitres of the 1.050 g/ml solution were given 
into an ultracentrifuge tube. Through a lumbar puncture needle, nine millilitres of the 
1.090 g/ml solution were gently layered under the 1.050 g/ml solution. Finally, nine 
millilitres of the 1.12 g/ml solution were brought to the bottommost position and ten 
millilitres of the post-nuclear supernatant were applied on the top of the Percoll 
gradient. After centrifugation at 20,000 x g for 40 minutes four bands, containing the 
different subcellular structures, were distinguishable (see figure 4). 
Table 2: Preparation of Percoll solutions of different densities (three-layer) 
Percoll stock 
solution [ml] 
Relaxation buffer 
(10 X) [ml] 
H20 [ml] Final density 
[g/ml] 
10.27 3 16.73 1.050 
19.58 3 7.42 1.090 
26.55 3 0.45 1.12 
 
4.2.3.3 Four-layer Percoll gradient 
Four different density solutions, each with a volume of 10 ml and a pH of 7.0, were 
prepared as shown in table 3. The supernatant, resulting from the centrifugation step 
after nitrogen cavitation, was diluted 1 + 1 with the 1.11 g/ml Percoll solution. The 
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resulting mixture had a density of 1.055 g/ml. Nine millilitres of the 1.03 g/ml solution 
were given in the centrifugation tube and was underlayered with nine millilitres of the 
prepared sample-Percoll mixture. Again, nine millilitres of the 1.09 g/ml Percoll were 
given under the resulting liquid layers. In the last step, nine millilitres of the solution 
with the highest density were brought to the bottom of the ultracentrifuge tube. All 
underlying steps were performed with a lumbar puncture needle. Like the three-layer 
gradient, the centrifugation took 40 minutes at 20,000 x g by turned down deceleration 
and acceleration. 
Table 3: Preparation of Percoll solutions of different densities (four-layer) 
Percoll stock 
solution [ml] 
Relaxation buffer 
(10 X) [ml] 
H20 [ml] 
Final density  
[g/ml] 
1.86 1 7.14 1.03 
6.44 1 2.66 1.09 
7.96 1 1.04 1.11 
8.73 1 0.27 1.12 
 
4.2.4 Fractionation and removal of Percoll 
The fractions were collected millilitre by millilitre, whereby every millilitre represented 
a single fraction. In the end, 36 fractions were originated. Since the remaining Percoll 
caused a problem in western blotting, we removed it by ultracentrifugation. After this 
centrifugation step at 100,000 x g for 45 minutes, the Percoll formed a hard pellet at the 
bottom, whereas the fractions were found above the Percoll and could be collected. 
After the addition of 10 % glycerol, the fractions were stored at -20 °C. 
 
4.3 Analysis of subcellular marker proteins 
The 36 fractions had to be summarized to the final fractions, optimally containing only 
one single type of the desired cell organelles. Using the ELISA technique, we detected 
specific marker proteins to localise the organelles within the gradient. The exact borders 
had to be determined individually for every gradient, since they varied among different 
experiments and donors. Myeloperoxidase was used as a marker for azurophilic 
granules, neutrophil gelatinase-associated lipocalin (NGAL) for specific granules, HLA 
for the plasma membrane, and the gelatinase granules were defined by their high 
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content of matrix metalloproteinase 9 (MMP-9). The secretory vesicles were localized 
by the detection of albumin. The frozen fractions were thawed on ice and all ELISAs 
were run in duplicates. 
 
4.4 Western blot 
4.4.1 SDS-PAGE 
The sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) makes it 
possible to separate proteins in an electric field according to their molecular mass. In 
order to eliminate charge differences, the proteins were boiled in sample loading buffer 
containing SDS. SDS is an anionic detergent, which binds uniformly along polypeptide 
chains and masks the proteins' intrinsic charge. This leads to an approximately constant 
net charge per unit mass. Additionally, we added a reducing reagent to the loading 
buffer to ensure a better unfolding of the proteins.(88) Beside its purpose in sample 
preparation, the loading buffer becomes important during the loading process: it weighs 
down the samples and prevents them from floating in the buffer solution. Secondly, the 
sample buffer contains a dye, which moves faster than the proteins and helps to stop the 
electrophoresis in time. We began the sample preparation with a DNase I treatment. 
Therefore, 5 µl of DNase I were added to a sample volume of 50 µl and the mixture was 
incubated for 30 minutes at room temperature. Afterwards, 6 µl of NuPage reducing 
agent and 24 µl NuPage sample buffer were added. The samples were kept for 
20 minutes at 60 °C in the heating block. We loaded 20 µl samples and 8 µl prestained 
standard into the wells and run the electrophoresis at 200 volt for 35 minutes. We chose 
a discontinuous 4 - 12 % polyacrylamide gel for the separation. The gel's section with 
the lower percentage acts as a stacking gel. It has a large pore size and it is slightly 
acidic. The lower gel, called the separating or resolving gel, is more basic and has the 
higher polyacrylamide content. The purpose of the stacking gel is to concentrate the 
samples into a tight band during the first minutes of the electrophoresis. The glycine of 
the tris-bis buffer forms a zwitterion (trailing ion) in the low pH of the stacking gel. The 
chloride ion, which is mobile in both gels (leading ion), moves faster than the glycine 
and the electric field strength between glycine and chloride forces the SDS surrounded 
proteins towards the resolving gel. When the glycine molecules enter the alkaline 
resolving gel, their amphoteric character turns into anionic. This causes an increase of 
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mobility and the glycine overtakes the proteins. Now, the proteins are the main carrier 
of the electric current and get separated in the fine-meshed resolving gel according to 
their molecular mass.(87,88) The molecular weight of the proteins was estimated by 
comparison of their electrophoretic migration to a standard of known molecular weight. 
 
4.4.2 Transfer of the proteins 
After the length-dependent gel electrophoretic separation of the denatured proteins, we 
blotted (transferred) those from the polyacrylamide gel onto a PVDF membrane. We 
used the ‘iBlot dry Blotting System’, which works with an electric field and transfers 
the proteins within 6 minutes onto the membrane. 
 
4.4.3 Blocking and detection 
Non-specific binding sites were blocked by immersing the membrane in PBS-T 
supplemented with 5 % non-fat dried milk for three hours at room temperature. 
Afterwards, we washed three times for 5 minutes in PBS-T. The specific primary 
antibodies were diluted in PBS-T with 3 % non-fat dried milk and incubated overnight 
at 4 °C. In order to remove any unbound antibodies, the membrane was washed in 
PBS-T (4 x 10 minutes). In the second step of detection, a species-specific and HRP 
conjugated secondary antibody, diluted in PBS-T, was incubated for 2 hours. After four 
washing steps, we gave a luminol-containing ECL western blotting detection reagent on 
the membrane. HRP oxidises the luminol and brings it to an excited state. Luminol 
decays to ground state via light emitting. The light emission was detected by a 
photographic film. The exposure times varied from 30 seconds to 12 hours. 
 
4.5 Inflammasome in vitro stimulation 
4.5.1 Patients and controls 
Blood was obtained after informed consent and approval of the study by the ethics 
committee of the University of Tübingen. Four male Muckle–Wells syndrome (MWS) 
patients (mean age: 31 years) were studied. All patients had a classic clinical 
presentation of MWS. Control blood samples were obtained from healthy volunteers 
(n=13, mean age: 27 years). Since substantial interdonor variabilities in the IL-1β 
production and effects of even mild infections and allergies were already observed in 
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previous experiments, we used control subjects without known infections, inﬂammatory 
disorders, allergies, or recent medication history. Fresh whole blood was drawn from 
both, patients and controls, by antecubital venipuncture in heparinized plastic tubes at a 
standardized daytime. Since the obtained cell amounts were limited, it was not possible 
to run all subsequent assays for each donor. As a consequence, the cytokine 
measurements varied concerning their number of analysed samples. 
 
4.5.2 Stimulation of neutrophil granulocytes 
The neutrophil granulocytes were isolated from venous whole blood in a standardised 
manner and with great caution to prevent unspecific activation. The experiments were 
performed according to a previously published protocol for inflammasome 
stimulation(26). We stimulated highly purified neutrophils as well as traditional Ficoll 
isolated neutrophils. Initially, the suspension with the isolated cells was centrifuged at 
350 x g for 10 minutes and the pellet was resuspended in cRPMI medium. The cells 
were cultivated in 1.5 ml Eppendorf vials at a density of 20 x 106 cells per millilitre. 
This cell density was chosen since correspondingly high concentrations reduce the 
constitutive apoptotic rate of neutrophils.(4) The neutrophils were stimulated with LPS 
(10 ng/ml, diluted in cRPMI) for 4 hours at 37 °C and 5 % CO2. We always included a 
negative control to which we added pure cRPMI medium (see table 4). Subsequently, 
we stimulated the cells with ATP (5 mM) or nigericin (5 µM) for another 2 hours. In 
order to study the effects of the stimulants on their own, we also had approaches without 
the previous LPS treatment. Correspondingly, we performed stimulations only with 
LPS. After an altogether incubation time of 6 hours, the vials were centrifuged at 
350 x g for 10 minutes at 4 °C. The cell free supernatants were frozen at -20 °C until 
required for further processing. To enhance protein stability, we added 10 % glycerol 
and a mixture of protease inhibitors to the samples. 
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Table 4: Stimulation procedure 
 First stimulation (4 h) Second stimulation (2 h) 
Control Medium Medium 
1. LPS ATP 
2. LPS Nigericin 
3. Medium LPS 
4. Medium ATP 
5. Medium Nigericin 
 
4.5.3 Stimulation of PBMCs 
PBMCs were separated by Ficoll density centrifugation and washed twice in RPMI 
medium. The pellet was resuspended in cRPMI and the cell count was determined. 
Unlike the neutrophils, the PBMCs were brought to a cell density of one million per 
millilitre. The subsequent stimulation procedure was similar to the one described for the 
neutrophil granulocytes (see table 4). 
 
4.5.4 Stimulation under inhibited conditions 
Since serine proteases are abundantly present in human neutrophils and have been 
shown to cleave some precursors of interleukin-1 family members(17,37,76,86), we 
analysed the contribution of the serine proteases to the generation of IL1ß, -1α, -18, and 
-33 in highly purified neutrophils compared to autologous PBMCs by adding the serine 
protease inhibitor PMSF. In parallel, we used the pan-caspase inhibitor Z-VAD-FMK to 
block the proteolytic activity especially of caspase-1. Neutrophils and PBMCs were 
prepared as described. We employed 50 µM Z-VAD-FMK and 1 mM PMSF and added 
the inhibitors prior to the LPS stimulation. To make the results better comparable we 
also stimulated simultaneously without inhibitors. 
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Table 5: Stimulation procedure with inhibitors 
 First stimulation (4 h) Second stimulation (2 h) 
Control Medium Medium 
1. LPS ATP 
2. LPS Nigericin 
4. Z-VAD-FMK + LPS ATP 
5. Z-VAD-FMK + LPS Nigericin 
7. PMSF + LPS ATP 
8. PMSF + LPS Nigericin 
 
4.5.5 Quantification of the interleukin production 
The interleukin production of the neutrophils and PBMCs during the stimulations was 
quantified using ELISA technique. Therefore, we analysed the supernatants, which were 
separated from the cells directly after the six hours of stimulation. 
 
4.6 ELISA 
All our performed enzyme-linked immunosorbent assays (ELISAs) were based on the 
antibody sandwich technique. Here, the capture antibody, specific to the analyte of 
interest, is immobilized to the solid surface of the microtitre plate. The non-specific 
binding sites were blocked with a BSA-containing reagent. During sample incubation, 
the antigens were binding to the immobilized capture-antibodies. After any unbound 
analyte was removed, the biotinylated detection antibody completed the sandwich by 
binding to a different epitope of the measured protein. Following a further washing step, 
streptavidin-HRP was added. HRP, which bound via streptavidin-biotin interaction, 
converted a chromogenic substrate into a blue colour product. The progressive colour 
development was stopped by the addition of an acid, which turned the colour from blue 
to yellow. The intensity of the produced colour was directly proportional to the 
concentration of the measured protein. 
 
The described principle was employed by the DuoSet ELISAs, which we most 
commonly used. The IL-18, IL-1α, and the albumin ELISA utilized the same 
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mechanisms but in slightly modified way. The degree of sample dilution (undiluted up 
to a dilution of 1:50,000) depended on the detected protein but also varied within 
different experiments. To prevent biased results, we applied samples, standards, and all 
reagents simultaneously with a multichannel pipette. Between each step, the ELISA 
plates were washed four times in wash buffer (4 x 400 µl). The buffer was poured out 
over a sink and the plates were tapped against paper towels to remove remaining drops. 
All our ELISAs worked with HRP and the visualising reagent TMB. Thus, optical 
density was measured at a wavelength of 450 nm. The wavelength correction was set to 
570 nm. We averaged the duplicate readings for standards as well as for the samples and 
subtracted the average zero. A four parameter standard curve was generated for each set 
of samples. All steps were performed at room temperature. 
 
4.6.1 DuoSet ELISAs: NGAL, MMP-9, MPO, IL-1ß, and IL-33 
A 96-well microplate was coated during an overnight incubation with 100 µl capture 
antibody. After blocking with 300 µl reagent diluent, 100 µl sample or standard were 
given into the wells. After two hours of incubation unbound substances were removed. 
100 µl of the diluted detection antibodies were incubated for another two hours. The 
streptavidin-HRP solution (100 µl) was incubated for 20 minutes. After a final washing 
step, 100 µl substrate solution were given on the plate. We stopped the reaction after 
20 minutes with 50 µl stop solution. 
 
4.6.2 Albumin and IL-18 ELISAs 
The monoclonal capture antibody was pre-coated onto the provided microplate. 100 µl 
sample or standard were given respective the plate layout into the wells. After one hour 
of incubation the plate was washed. Subsequently, 100 µl of the HRP conjugated 
detection antibodies were given into each well. After the incubation time (albumin: 30 
minutes; IL-18: 60 minutes) a wash step was performed. Bound HRP was assayed by 
addition of 100 µl TMB. We stopped the reaction after 10 minutes (albumin ELISA) or 
after 30 minutes (IL-18 ELISA) with 100 µl stop solution. 
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4.6.3 IL-1α ELISA 
The IL-1α ELISA was similar to the performed procedure of the DuoSet ELISAs, only 
some incubation periods differed: the streptavidin-HRP solution was incubated for 
30 minutes and the TMB substrate for 10 minutes. 
 
4.6.4 HLA ELISA 
The plate was coated with rabbit anti-human ß2-microglobulin antibodies (dilution: 
1:1000) during an overnight incubation step. Mouse anti-human HLA-ABC was used in 
a dilution of 1:750 as primary detection antibodies, anti-mouse HRP-labelled antibodies 
(dilution 1:1500) as secondary detection antibodies. We did not use standards for this 
ELISA; we analysed the optical density values instead. The remaining procedure was 
handled like described for the DuoSet ELISAs.  
 
4.7 Determination of total protein concentrations 
For the quantitative measurement of the fractions' total protein we used the Bradford 
method. Here, the dye Coomassie Brilliant Blue forms complexes with proteins, leading 
to a conversion from reddish to a blue colour. The absorption maximum shifts from 
465 nm towards longer wavelengths. The increased absorbance at 595 nm is 
proportional to the amount of bound Coomassie blue and by association to the protein 
concentration in the solution. For every series of measurements, we created a new 
standard curve. It involved six points from blank up to 20 µg/ml BSA. For the protein 
detection, we added 200 µl reagent to 80 µl of standard or diluted sample, mixed 
thoroughly, and incubated for 5 minutes at room temperature. The ratio of the 
absorbance, 595 nm over 450 nm, was calculated and the amount of protein was 
determined in relation to the standards. 
 
4.8 Statistical analysis 
Data are expressed as mean ± SEM. Statistical significance of differences was 
determined by one-way ANOVA followed by Bonferroni’s post-hoc test. In all tests P < 
0.05 was considered to be statistically significant. The significant levels were denoted 
with asterisks: P < 0.05 (*), P < 0.01 (**), and P < 0.001 (***). 
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5. Results 
5.1 IL-1ß concentrations in cell culture supernatants 
5.1.1 IL-1ß secreted by neutrophils from healthy donors 
Blood was collected from healthy volunteers and the purified neutrophil granulocytes 
were stimulated according to the two-hit theory of inflammasome activation. These 
double stimulated cells increased their IL-1ß production highly significant in 
comparison to the negative, unstimulated controls (see figure 5). The average 
concentration of IL-1ß in supernatants derived from neutrophils treated with LPS + ATP 
was 14 pg/ml. LPS/nigericin treatment had the largest effect on the IL-1ß production: the 
supernatants obtained from these cells showed an average IL-1ß concentration of 
22 pg/ml. Neither ATP, nor nigericin or LPS alone raised the IL-1ß production as 
observed in the double stimulations; the IL-1ß concentrations were considerably lower 
here. The smallest IL-1ß levels were secreted in response to the nigericin stimulation. 
 
Figure 5: IL-1ß secreted by neutrophils from healthy donors. Neutrophil granulocytes 
were isolated from healthy donors and stimulated with LPS + ATP and with LPS + 
nigericin (black bars) as well as with LPS, ATP, or nigericin alone (grey bars). The 
amount of released IL-1ß after an altogether incubation time of 6 hours was determined 
using ELISA technique. Concentrations are given as pg/ml (mean ± SEM). 
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5.1.2 IL-1ß secreted by healthy neutrophils under inhibited conditions 
The study was performed to investigate the involvement of inflammasomes and serine 
proteases in the maturation of IL-1ß in neutrophils. To gain a better understanding about 
the mechanisms, we stimulated under addition of Z-VAD-FMK and PMSF. The blood 
was collected from three healthy donors. Again, as in experiment 5.1.1, the IL-1ß 
concentrations were significantly increased after stimulation with LPS + ATP or 
LPS + nigericin. Both inhibitors, PMSF as well as Z-VAD-FMK, affected the IL-1ß 
production (see figure 6). The LPS/ATP-induced IL-1ß secretion was reduces to one-
third by Z-VAD-FMK; PMSF decreased the IL-1ß production to one quarter. The 
LPS/nigericin stimulated cells produced on average one-third less under serine protease 
inhibition, whereas the LPS/nigericin-induced IL-1ß secretion stopped almost 
completely under caspase inhibition. 
 
Figure 6: IL-1ß secreted by healthy neutrophils under inhibited conditions. Neutrophils 
were stimulated with LPS + ATP or LPS + nigericin (black bars) with or without 
pretreatment with a serine protease inhibitor (PMSF, 1 mM; light grey bars) or a 
caspase inhibitor (Z-VAD-FMK, 50 µM; dark grey bars). The amount of IL-1ß produced 
and released by the cells was measured using ELISA technique. Concentrations are 
given as pg/ml (mean ± SEM). 
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5.1.3 IL-1ß secreted by neutrophils from MWS patients 
To compare the IL-1ß production levels of healthy neutrophils with CIAS1 mutated 
cells, we stimulated highly purified neutrophil granulocytes of 13 healthy donors and 
four MWS patients. Both groups increased the IL-1ß production in response to 
LPS/ATP stimulation as well as to the LPS/nigericin treatment. However, the CIAS1 
mutated cells secreted in total less IL-1ß upon stimulation than the healthy cells (see 
figure 7). Treatment with LPS/nigericin had the largest impact on the IL-1ß production 
in both batches: the MWS neutrophils produced on average 12 pg/ml of IL-1ß (healthy 
control cells: 23 pg/ml). LPS/ATP showed lower effects: the average concentration 
achieved by MWS neutrophils was 7 pg/ml; the healthy cells produced 13 pg/ml. In 
contrast to these finding were the results found in the untreated controls of both groups: 
here, the MWS neutrophils produced about twice as much IL-1ß than the healthy cells 
did. 
 
Figure 7: IL-1ß secreted by neutrophils from MWS patients. Neutrophils, isolated from 
13 healthy donors (white bars) and from four MWS patients (black bars), were 
stimulated with LPS + ATP and with LPS + nigericin. The amount of released IL-1ß 
was determined using ELISA technique. Concentrations are given as pg/ml (mean ± 
SEM). 
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5.1.4 IL-1ß secreted by PBMCs from healthy donors 
We stimulated PBMCs of healthy donors with LPS followed by ATP or nigericin. These 
double stimulated cells increased their IL-1ß secretion highly significant in comparison 
to the negative, unstimulated controls. The average IL-1ß concentration in supernatants 
after LPS/ATP stimulation was 8,750 pg/ml. The supernatants obtained from cells 
stimulated with LPS + nigericin contained about 10,000 pg/ml IL-1ß. Neither ATP, nor 
nigericin or LPS alone increased the IL-1ß production: the detected IL-1ß 
concentrations were comparable to the ones found in the supernatants of the 
unstimulated cells (see figure 8). 
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Figure 8: IL-1ß secreted by PBMCs from healthy donors. PBMCs were isolated from 
healthy donors and stimulated with LPS + ATP, or LPS + nigericin, (black bars) as well 
as with LPS, ATP, or nigericin alone (grey bars). The IL-1ß concentrations are given as 
pg/ml (mean ± SEM) and were determined by ELISA technique. 
 
5.1.5 IL-1ß secreted by healthy PBMCs under inhibited conditions 
The PBMC fraction was isolated from three healthy donors and stimulated under 
different conditions. The cells increased their IL-1ß secretion in response to stimulation 
with LPS + ATP as well as to LPS + nigericin. The presence of the serine protease 
inhibitor PMSF had no inhibitory influence on the production; the concentrations were 
comparable to the ones found in the analogues stimulations without the inhibitor, 
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whereas the IL-1ß synthesis stopped completely under caspase inhibition (see figure 9). 
The addition of Z-VAD-FMK tended to result in even lower cytokine concentrations 
than the ones found in the supernatants of the untreated cells. 
 
Figure 9: IL-1ß secreted by healthy PBMCs under inhibited conditions. PBMCs were 
isolated from three healthy donors and stimulated with LPS + ATP or LPS + nigericin 
(black bars) and with or without the pretreatment with a serine protease inhibitor 
(PMSF, 1 mM; light grey bars) or a caspase inhibitor (Z-VAD-FMK, 50 µM). The IL-1ß 
concentrations were measured by ELISA and are given as pg/ml (mean ± SEM). 
 
5.1.6 IL-1ß secreted by PBMCs from MWS patients 
With the purpose to compare the IL-1ß production levels of healthy PBMCs with CIAS1 
mutated PBMCs, we collected blood from ten healthy donors and four MWS patients. 
Both groups increased the IL-1ß production significantly in response to the LPS/ATP 
stimulation as well as to the LPS/nigericin treatment. However, the CIAS1 mutated cells 
produced in total less IL-1ß upon the stimulation compared to the values achieved by 
the healthy cells (see figure 10). In contrast to these finding were the results found in the 
unstimulated controls of both groups: here, the MWS PBMCs produced about twice as 
much IL-1ß than the healthy cells did. 
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Figure 10: IL-1ß secreted by PBMCs from MWS patients. PBMCs were isolated from 
ten healthy donors (white bars) and four MWS patients (black bars). The cells were 
stimulated with LPS + ATP as well as with LPS combined with nigericin. The amount of 
released IL-1ß was measured using ELISA technique. Concentrations are given as pg/ml 
(mean ± SEM).  
 
5.2 IL-1α concentrations in cell culture supernatants 
5.2.1 IL-1α secreted by healthy and MWS neutrophils  
No detectable concentrations of IL-1α were found in the supernatants obtained from 
highly purified neutrophils, neither in the healthy nor in MWS group. 
 
5.2.2 IL-1α secreted by PBMCs from healthy donors 
We stimulated PBMCs of healthy donors with LPS followed by ATP or nigericin. These 
double stimulated cells increased their IL-1α secretion significantly in comparison to the 
negative, unstimulated controls. The average IL-1α concentration in the supernatants 
after LPS + ATP stimulation was 780 pg/ml. The supernatants obtained from cells, which 
were stimulated with LPS + nigericin had on average about 1,200 pg/ml of IL-1α (see 
figure 11). Neither ATP, nor nigericin or LPS alone increased the IL-1α production as it 
was observed in cells stimulated with the stimulant combination. The IL-1α 
concentrations in these stimulations were comparable to the ones found in the 
supernatants of the untreated controls. 
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Figure 11: IL-1α secreted by PBMCs from healthy donors. PBMCs were stimulated with 
LPS + ATP or LPS + nigericin, (black bars) as well as with LPS, ATP, or nigericin 
alone (grey bars). IL-1α concentrations in the cell culture supernatants were determined 
by ELISA and are given as pg/ml (mean ± SEM).  
 
5.2.3 IL-1α secreted by healthy PBMCs under inhibited conditions 
We collected whole blood from two healthy volunteers and isolated the PBMC fraction. 
The mononuclear cells were stimulated with a combination of LPS and either ATP or 
nigericin. To investigate to what extent caspase-1 is involved in the cleavage and 
activation of IL-1α, we stimulated also under addition of Z-VAD-FMK. The cells 
increased their IL-1α production significantly in response to LPS/ATP as well as to the 
LPS/nigericin stimulation. LPS/nigericin treatment resulted in an average IL-1ß 
concentration of 1,450 pg/ml. The LPS/ATP stimulated cells produced on average 
950 pg/ml. In the untreated controls an averaged IL-1α concentration of 35 pg/ml was 
found. The additional pretreatment with Z-VAD-FMK resulted in a stagnation of the IL-
1α production (see figure 12). 
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Figure 12: IL-1α secreted by healthy PBMCs under inhibited conditions. PBMCs were 
isolated from healthy donors and stimulated with LPS + ATP or LPS + nigericin (black 
bars). In order to investigate the influence of caspases in the maturation process of IL-
1α we added Z-VAD-FMK (50 µM) to the stimulations. The amount of IL-1α secreted by 
the cells was measured by ELISA. Concentrations are given as pg/ml (mean ± SEM). 
 
5.2.4 IL-1α secreted by PBMCs from MWS patients 
This experiment was performed with the purpose to compare the IL-1α production 
levels of PBMCs from healthy donors and MWS patients. Therefore, whole blood was 
collected from three healthy volunteers and three MWS patients. The PBMC fraction 
was isolated and stimulated with LPS + ATP and LPS + nigericin. Both groups 
increased their IL-1α production in response to the stimulations. The cells carrying the 
CIAS1 mutation produced on average greater amounts of the cytokine than the healthy 
PBMCs did. The IL-1α concentrations in supernatants derived from MWS PBMCs after 
LPS/ATP or LPS/nigericin treatment ranged around 610 pg/ml (see figure 13). The 
healthy control cells produced upon stimulation on average 320 pg/ml IL-1α. We also 
found higher IL-1α levels in the cell culture supernatants of the unstimulated MWS 
PBMCs compared to the healthy untreated cells. 
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Figure 13: IL-1α secreted by PBMCs from MWS patients. PBMCs were isolated from 
three healthy donors (white bars) and three MWS patients (black bars) and stimulated 
with LPS + ATP or LPS + nigericin. The IL-1α concentrations in the cell culture 
supernatants were determined by ELISA and are given as pg/ml (mean ± SEM). 
 
5.3 IL-18 concentrations in cell culture supernatants 
5.3.1 IL-18 secreted by neutrophils from healthy donors 
We stimulated highly purified neutrophils with LPS followed by ATP or nigericin. 
These double stimulated neutrophils produced around 350 pg IL-18 per millilitre (see 
figure 14). The IL-18 concentrations detected in the supernatants of the unstimulated 
control cells were on average 385 pg/ml. Thus, neither the stimulation with LPS + ATP 
nor with LPS + nigericin influenced the anyhow high IL-18 baseline production. The 
cells treated with LPS, ATP, or nigericin alone produced IL-18 concentrations ranging 
from 290 to 440 pg/ml. 
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Figure 14: IL-18 secreted by neutrophils from healthy donors. Neutrophil granulocytes 
were highly purified and stimulated with LPS + ATP, or LPS + nigericin, (black bars) 
as well as with LPS, ATP, or nigericin alone (grey bars). IL-18 levels in the cell culture 
supernatants were determined using ELISA technique. Concentrations are given pg/ml 
(mean ± SEM). 
 
5.3.2 IL-18 secreted by neutrophils from MWS patients 
This experiment was performed with the purpose to compare IL-18 production levels of 
healthy neutrophils with CIAS1 mutated cells. We stimulated the highly purified 
neutrophils with LPS + ATP or with LPS + nigericin. Both groups, healthy and MWS, 
did not change their IL-18 production considerably upon stimulation. However, the 
IL-18 concentrations detected in supernatants removed from CIAS1 mutated neutrophils 
were altogether on a lower level. Untreated healthy neutrophils produced in average 
400 pg/ml of IL-18; the stimulated MWS cells about 500 pg/ml (see figure 15). 
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Figure 15: IL-18 secreted by neutrophils from MWS patients. Neutrophils were isolated 
from three healthy donors (white bars) and three MWS patients (black bars). The cells 
were highly purified and stimulated with LPS in combination with ATP or nigericin. The 
IL-18 concentrations in the cell culture supernatants were determined by ELISA and are 
given as pg/ml (mean ± SEM). 
 
5.3.3 IL-18 secreted by PBMCs from healthy donors 
We stimulated PBMCs with LPS followed by ATP or nigericin as well as with LPS, ATP 
and, nigericin alone. The IL-18 concentrations were significantly increased in the 
supernatants derived from these double stimulated cells. The average IL-18 
concentration in supernatants after LPS/ATP stimulation was 195 pg/ml (see figure 16). 
The supernatants obtained from cells stimulated with LPS + nigericin had on average 
about 150 pg/ml of IL-18. Neither ATP nor nigericin or LPS alone raised the IL-18 
production like it was observed in cells stimulated with the stimulant combination. The 
IL-18 concentrations released by PBMCs incubated with only one stimulant ranged 
from below detection limit up to 5 pg/ml (unstimulated controls: 3 pg/ml). 
RESULTS 
 
47 
 
Figure 16: IL-18 secreted by PBMCs from healthy donors. PBMCs were stimulated with 
LPS + ATP or LPS + nigericin, (black bars) as well as with LPS, ATP, or nigericin 
alone (grey bars). The IL-18 concentrations in the cell culture supernatants were 
determined using ELISA technique and are given as pg/ml (mean ± SEM). 
 
5.3.4 IL-18 secreted by healthy PBMCs under inhibited conditions 
We collected whole blood from healthy volunteers and isolated the PBMC fraction. The 
mononuclear cells were stimulated with a combination of LPS and either ATP or 
nigericin. To investigate to what extent caspase-1 is involved in the cleavage and 
activation of pro-IL-18, we stimulated also after Z-VAD-FMK pretreatment. In both 
stimulations, LPS/ATP and LPS/nigericin, the IL-18 concentrations were on average 
around 185 pg/ml (see figure 17). The addition of Z-VAD-FMK resulted in an almost 
complete stagnation of the IL-18 production with concentrations ranging under 5 pg/ml 
(untreated controls: 0 pg/ml). 
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Figure 17: IL-18 secreted by healthy PBMCs under inhibited conditions. PBMCs were 
isolated from two healthy donors and stimulated with LPS + ATP as well as 
LPS + nigericin (black bars) and with or without pretreatment with a caspase inhibitor 
(Z-VAD-FMK, 50 µM; grey bars). The IL-18 concentrations were measured by ELISA 
and are given as pg/ml (mean ± SEM). 
 
5.3.5 IL-18 secreted by PBMCs from MWS patients 
This experiment was performed with the purpose to compare IL-18 production levels of 
healthy PBMCs with CIAS1 mutated cells. The PBMC fractions were isolated and 
stimulated with LPS + ATP and LPS + nigericin. The PBMCs obtained from MWS 
patients produced consistently higher levels of IL-18. The average IL-18 production of 
stimulated MWS PBMCs was about 400 pg/ml and thus approximately twice as high as 
the one of the healthy cells (see figure 18). The untreated MWS PBMCs produced 
45 pg/ml. No IL-18 was detectable in the supernatants of the unstimulated healthy cells. 
RESULTS 
 
49 
U
nt
re
at
ed
LP
S 
+ 
A
TP
LP
S 
+ 
N
ig
er
ic
in
U
nt
re
at
ed
LP
S 
+ 
A
TP
LP
S 
+ 
N
ig
er
ic
in
 
Figure 18: IL-18 secreted by PBMCs from MWS patients. PBMCs were isolated from 
three healthy donors (white bars) and three MWS patients (black bars). The cells were 
stimulated with a LPS/ATP combination as well as with LPS combined with nigericin. 
IL-18 concentrations were measured in the cell culture supernatants by ELISA 
technique and are given as pg/ml (mean ± SEM).  
 
5.4 IL-33 concentrations in cell culture supernatants 
The supernatants obtained from neutrophils as well as from PBMCs showed in all cases 
IL-33 concentrations below or very close the assay’s detection limit. 
 
5.5 IL-1ß plasma levels in patients with MWS 
We measured no differences between the IL-1ß plasma levels of MWS-patients (n=4) 
and healthy controls (n=10). Both groups achieved average concentrations of 4 pg/ml. 
 
5.6 IL-1ß production by neutrophils of different purity degrees  
We collected blood from healthy volunteers and isolated neutrophil granulocytes with 
the common Ficoll fractionation method. In four of 14 cases, we simulated the cells 
after this Ficoll separation. The neutrophils of the other 10 donors were undertaken an 
additional purifying step with EasySep. The purity of those neutrophils was > 98 %, as 
assessed by May-Grünwald-Giemsa stain and flow cytometry. Both groups were 
stimulated and the IL-1ß concentrations in the supernatants were measured. The IL-1β 
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protein levels released by the highly purified human neutrophils were substantially 
lower compared to the concentrations obtained by the partially purified neutrophils (see 
figure 19). The cells, which were only isolated with Ficoll, produced in average 
300 pg/ml of IL-1ß due to stimulation. The highly purified cells released under the same 
conditions 20 times less IL-1ß, on average 15 pg/ml. 
 
Figure 19: IL-1ß production by neutrophils of different purity levels. IL-1ß 
concentrations in cell culture supernatants after in vitro stimulation. Highly purified 
(white bars) and traditional Ficoll isolated neutrophils (black bars) were stimulated 
with LPS + ATP or LPS + nigericin. Concentrations are given as pg/ml (mean ± SEM). 
 
5.7 Neutrophil subcellular fractionation 
5.7.1 Analysis of the subcellular marker protein MPO 
Preliminary tests demonstrated that a sample dilution of 1:30,000 was most suitable for 
the quantification of the granule protein MPO. The highest MPO values were achieved 
in fraction 2 to 8 (see figure 20). Samples 12 to 36, which were obtained from upper 
regions of the gradient, showed MPO concentrations under detection limit. 
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Figure 20: MPO distribution profile of the fractions. After the subcellular fractionation 
of highly purified neutrophil granulocytes on a four-layer Percoll density gradient, the 
gradient was divided into 36 fractions given on the x-axis. Each fraction was assayed 
for its content of MPO, the marker protein for the primary granules. Concentrations are 
given as µg/ml. 
 
5.7.2 Analysis of the subcellular marker protein HLA 
After initial test runs to estimate the dimension of the fractions' HLA concentration, we 
decided to perform the measurements in a sample dilution of 1:10,000. Since no suitable 
standard was available, we limited ourselves to interpret the optical densities of the 
assay. An increase of absorbance was observed from the 19th fraction onwards (see 
figure 21). These results suggested that the rare fractions, which were collected from the 
upper regions of the gradient, contained the plasma membrane. 
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Figure 21: HLA distribution profile of the fractions. Highly purified neutrophil 
granulocytes were lysed through nitrogen cavitation. After the subcellular fractionation 
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on a four-layer Percoll density gradient, the HLA content of the fractions (dilution 
1:10,000) was determined by ELISA. HLA was used as marker protein for detection of 
the plasma membrane. Values are given as optical density (OD). 
 
5.7.3 Analysis of the subcellular marker protein MMP-9 
The tertiary granules are characterized by their high content of gelatinase (MMP-9). 
Preliminary tests demonstrated that a sample dilution of 1:10,000 was most suitable for 
the quantification of this granule protein. The results showed that fraction 19 to 23 
contained, with an average concentration of 22 µg/ml, the highest MMP-9 amounts (see 
figure 22). The remaining fractions showed MMP-9 levels under 6 µg/ml. 
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Figure 22: MMP-9 distribution profile of the fractions. After the subcellular 
fractionation of highly purified neutrophil granulocytes on a four-layer Percoll density 
gradient, the gradient was divided into 36 fractions given on the x-axis. Each fraction 
was assayed for its content of MMP-9, the marker protein for the tertiary granules. 
Concentrations are given as µg/ml. 
 
5.7.4 Analysis of the subcellular marker protein NGAL 
Secondary granules were characterized by their high content of NGAL. After the 
performance of test runs, we decided to quantitate the protein in a fraction dilution of 
1:20,000. The results showed a clear tendency to higher NGAL concentrations in the 
fractions 10 to 17 (see figure 23). In these fractions the average NGAL concentration 
ranged around 29 µg/ml. The remaining fractions had NGAL levels under 10 µg/ml. 
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Figure 23: NGAL distribution profile of the fractions. Highly purified neutrophil 
granulocytes were lysed through nitrogen cavitation. After the subcellular fractionation 
on a four-layer Percoll density gradient, the 36 fractions were assayed for NGAL, the 
marker protein for secondary granules. Concentrations are given as µg/ml. 
 
5.7.5 Analysis of the subcellular marker protein albumin 
The secretory vesicles, which are generated by endocytosis, are detected by the 
measurement of the plasma protein albumin. The ELISA was run in a sample dilution of 
1:200. The result showed an increased albumin concentration from fraction 17 onwards 
(see figure 24). The highest values were achieved in fraction 25 to 30 with average 
concentrations of 200 µg/ml.  
 
Figure 24: Albumin distribution profile of the fractions. After centrifugation, the four-
layer Percoll density gradient was fractionated in 36 parts. Each fraction was assayed 
for albumin, the marker protein for secretory vesicles. Concentrations are given as µg/ml. 
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5.7.6 Definition of the final fractions 
To allocate the fractions to a particular subcellular structure, we compared the results of 
the different markers proteins (see figure 25). The final fraction were defined as listed in 
table 6. 
 
Figure 25: Distribution profiles of all marker proteins. For sake of clarity, the fractions 
were summarised to a total number of 18. The employed markers were: MPO for 
primary granules, NGAL for secondary granules, MMP-9 for tertiary granules, albumin 
for secretory vesicles, and HLA for the plasma membrane. The concentrations for each 
protein are given as measured concentration in the fraction relative to the maximal 
concentration of the marker protein. 
 
Table 6: Definition of the final fractions 
Subcellular structure: Fraction 
Primary granules (marker protein: MPO) 1–9 
Secondary granules (marker protein: NGAL) 10–17 
Tertiary granules (marker protein: MMP-9) 18–23 
Secretory vesicles (marker protein: albumin) 24–29 
Plasma membrane (marker protein: HLA) 30–36 
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5.7.7 Further subdivision of a four-layer Percoll gradient 
To improve the efficiency of the subcellular fractionation procedure, we tried a 
demarcation of the plasma membrane from the cytosolic fraction within the four-layer 
Percoll gradient. For that reason, the last 7 fractions were analysed for their content of 
MICA, a component of the plasma membrane, using western blot analyses. However, 
MICA (molecular weight 43 kDa) was detectable in all analysed fractions with no 
observable concentration increase or decrease (see figure 26). Consequently, it did not 
succeed to separate the plasma membrane and the cytosolic fraction within the gradient. 
 
 
 
 
 
 
Figure 26: MICA immunoblot. The fractions, which were defined as plasma membrane 
containing fractions, were analysed for their content of MICA (43 kDa) in order to 
detect a possible shift from the plasma membrane to the cytosolic fractions. 
 
5.7.8 Subcellular localisation of inflammasome components 
To localise the inflammasome in neutrophils, the different subcellular components 
(cytosol, plasma membrane, secretory vesicles, and the three granules subtypes) were 
examined for the presence of ASC and caspase-1. The cytosol was obtained by a three-
layer Percoll gradient; the other organelles were separated in a four-layer gradient. The 
studies demonstrated that the investigated inflammasome components were expressed in 
the cytoplasm and in the fraction reflecting the plasma membrane together with the 
cytosol, but also colocalised in secretory vesicles, and tertiary granules (see figure 27 
and 28).  
 
 
 
 
 
 
Fraction 
40 kDa 
30   31       32           33            34             35           36 
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Figure 27: ASC immunoblot. Subcellular components of neutrophil granulocytes were 
analysed for their content of ASC (25 kDa), a protein of the inflammasomal multiprotein 
complex. ASC was detected in the cytosolic fraction (Cyt), in the fraction reflecting the 
plasma membrane together with the cytosol (PM/Cyt), in the secretory vesicles (SV), 
and in the tertiary granules (3°). No ASC could be detected in the secondary granules 
(2°) or in the fraction of the primary granules (1°). 
 
 
 
 
 
 
 
Figure 28: Caspase-1 immunoblot. Subcellular components of neutrophil granulocytes 
were analysed for their content of caspase-1 (20 kDa), a protein of the inflammasomal 
multiprotein complex. Caspase-1 was detected in the cytosolic fraction (Cyt), in the 
fraction reflecting the plasma membrane together with the cytosol (PM/Cyt), in the 
secretory vesicles (SV), and in the tertiary granules (3°). No caspase-1 could be 
detected in the secondary granules (2°) or in the fraction of the primary granules (1°). 
 
 
 
 
 
 
 
 
 
 
 
20 kDa 
     Cyt       PM/Cyt      SV        3°      2°           1° 
Subcellular 
structure 
25 kDa 
Subcellular 
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6. Discussion 
6.1 Neutrophil interleukin production  
Studying the inflammasome-associated IL-1 family cytokines, we observed that highly 
purified human neutrophils, equally to the PBMCs, significantly increased their IL-1ß 
production when the stimulation included a previous LPS priming step. However, both 
cell groups differed concerning their behaviour under the influence of the chemical 
inhibitors. In PBMCS, the caspase inhibitor Z-VAD-FMK completely suppressed the 
IL-1ß generation, while the inhibition of serine proteases was found to have no effect on 
the IL-1β release. The neutrophils showed the greatest response upon stimulation with 
LPS combined with nigericin (nigericin was about 2-fold more potent in triggering 
IL-1β release than ATP). Those cells, stimulated with LPS/nigericin, behaved in 
addition similar to the mononuclear cells under inhibitory influence: Z-VAD-FMK 
abrogated almost completely the IL-1ß generation, whereas PMSF showed no 
comparable effects. The LPS/ATP triggered neutrophil IL-1ß secretion decreased under 
serine protease inhibition as well as after treatment with the caspase inhibitor. We 
concluded that serine proteases play a role in neutrophil-derived, but not in PBMC-
derived IL-1β generation. The distinct involvement of serine proteases in the neutrophil 
IL-1ß production implies that the two inflammasome inducers, ATP and nigericin, differ 
substantially in their downstream mechanisms and hints at separate, stimulus 
depending, cytokine production pathways. These findings have a clear clinical relevance 
since they suggest that the therapeutic inhibition of caspases is not able to interfere with 
the whole spectrum of IL-1 production pathways. In inflammatory conditions in which 
neutrophils play a dominant role, especially in the acute phase of inflammation, a dual 
therapy with inhibition of caspase-1 and serine proteases could be more effective. 
 
IL-18 protein was already secreted by neutrophils at baseline conditions and the 
production could not be further increased through any inflammasome stimulation. Pro-
IL-18 is described to be constitutively expressed in PBMCs (50,58,65,66), whereas little is 
currently known about its expression profile in neutrophils. However, a recent study 
assumed also a constitutive expression of pro-IL-18 in human neutrophils.(70) The 
observed high IL-18 baseline production by neutrophils could be seen as a consequence 
of this constitutive protein expression. The incubation time of 6 hours and the isolation 
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procedure might have been sufficient to activate the constitutive expressed proenzyme. 
Furthermore, neutrophils possess, through their high content of proteinase 3, a potential 
additional option for IL-18 activation, which is not present in PBMCs. Another 
explanation for the consistent high IL-18 secretion might be the emergence of 
biologically inactive IL-18 forms. These peptides can be generated by caspase-3 or 
other proteases.(2,5) We are not sure if our used ELISA could differentiate between those 
IL-18 forms. 
 
The neutrophils in our study did not secrete detectable amounts IL-1α or IL-33 proteins. 
This could also be reasoned in the intracellular or cell surface-associated localisation of 
those cytokines, what makes them undetectable in the supernatants. 
 
6.2 PBMC interleukin production 
Our inflammasome in vitro studies achieved plausible results and confirmed the present 
knowledge about the maturation of the studied interleukins in PBMCs. The levels of all 
examined cytokines, with the exception of IL-33, increased considerably after 
inflammasome stimulation. Furthermore, we could demonstrate that a second stimulus, 
after a previous LPS priming step, strongly enhanced the proteolytic maturation and 
secretion of IL-1ß, IL-1α, and IL-18. Various studies, including our own, showed that 
treatment with caspase inhibitors, such as Z-VAD-FMK, dramatically reduces the 
production of interleukin-1 family cytokines in PBMCs. Consequently, the secretions 
fully depended on caspases and were independent of serine protease activities. 
 
6.3 Interleukin production by Muckle-Wells cells 
We observed that neutrophils isolated from MWS patients released significantly lower 
IL-1β and IL-18 levels upon stimulation compared to the investigated age-matched 
healthy control cells. These results were contrary to expectations if one considers the 
underlying MWS pathology, which is characterised by a constitutively increased 
NLRP3 inflammasome activity. However, it has to be taken into account that the 
mechanisms of the neutrophil interleukin production remain largely unexplored. 
Furthermore, little is known to what extent the different cell lines are involved in the 
MWS pathology. 
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Speculative explanations for the observed phenomenon are: 
• The mutated NLRP3 gene leads to a constitutive activated inflammasome at 
baseline conditions, rendering neutrophils unresponsive towards exogenous 
inflammasome activators. Inside-out counteracting mechanisms and so far 
unappreciated auto-regulatory feed-back loops between intrinsic and extrinsic 
inflammasome activation might exist here. These could restrict the 
inflammasomal responsiveness when the inflammasome is already activated. A 
potential source of such feedback loops could involve a down-regulation of cell 
surface receptors, like TLR4 or ATP receptors. 
• The constitutive over-activated inflammasome could simply lead to a 
consumption of pro-IL-1β, like a ‘secretory exhaustion’ of the neutrophils. 
• The mutated cryopyrin could be freed from the requirement of classical 
inflammasome activators. There is the possibility for completely different 
activators in vivo. 
• The stimulated neutrophils and PBMCs from MWS patients secreted lower IL-1ß 
levels than the simulated healthy controls but we observed a slightly higher IL-1ß 
baseline production in the CIAS1 mutated cells. The clinical appearance of MWS, 
which underlies high IL-1ß levels, might be explained by even this high IL-1ß 
production of unstimulated cells. IL-1ß is a hormone-like cytokine with an 
effective concentration ranging from less than 1 nM to 1 pM.(1) It is potent to 
induce a broad spectrum of systemic changes. It is easy to imagine that even small 
imbalances are sufficient for triggering clinical symptoms. 
• The number of experiments with MWS cells was severely limited. The reason 
behind was on the one hand the high blood quantity which was needed and on the 
other hand the rarity of the disease. We had four patients available and performed 
all MWS inflammasome stimulation experiments on a single day. The low 
interleukin production of MWS cells could also be due to a systematic error which 
occurred that day. Following errors are conceivable: 
• incorrect cell counts, 
• any cell interacting substance, 
• insufficient stimulation through decreased stimulant activity or too low 
concentrated stimulants, 
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• dilution effects through for instance the addition of too much glycerine or 
protease inhibitor. 
To what extent the increased IL-18 production by MWS PBMCs has medical relevance 
in the MWS pathophysiology needs to be investigated in further studies. 
 
6.4 Importance of neutrophil purity in inflammasome studies 
We used negatively selected highly purified neutrophils, since traditionally density 
gradient isolated neutrophils contain a substantial proportion of contaminating 
monocytes.(62,73) Monocytes produced upon stimulation on average 8,000 pg IL-1ß per 
millilitre, whereas the equal number of neutrophils under the same conditions secreted 
only 1 pg/ml. It is easy to imagine, how even small amounts of contaminating monocytes 
could distort the results and have to be considered when interpreting quantitative IL-1β 
results from traditional density gradient derived neutrophils. Furthermore, monocytes 
were previously found to influence neutrophils’ homeostasis as well as their 
responsiveness to inflammatory stimuli at several levels.(62,73) Monocyte-neutrophil 
interactions might amplify paracrine IL-1β production and modulate other cellular 
processes, an issue that requires further research. 
 
6.5 Subcellular fractionation 
Our western blot analysis demonstrated that highly purified human neutrophils 
expressed key components of the NLRP3 inflammasome machinery at protein level. 
Moreover, they showed that the inflammasomal components are stored, in addition to 
the already for a variety of cell types described cytoplasmic localisation(77), in secretory 
vesicles and tertiary granules. Secretory vesicles are uniquely sensitive for mobilisation 
and their special significance lies in providing a readily mobilisable reservoir of 
functional proteins. Our findings implicate that neutrophils are able to dynamically 
regulate their inflammasomes between intracellular stores and surface localisation. The 
subcellular mechanisms by which inflammasomes could interact with pro-IL-1β remain 
elusive, but given the role of secretory vesicles, it is tempting to speculate, that 
stimulated neutrophils translocate their inflammasome components to the cell surface, 
where the inflammasome could participate in pathogen recognition and uptake (see 
figure 30). This hypothesis is further supported by
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inflammasomes control the phagosomal functionality of macrophages due to infection 
with gram-positive bacteria.(81) 
 
Figure 29: Subcellular localisation of the inflammasome. The results of our subcellular 
fractionation study confirmed the already for other cell types described cytoplasmic 
localisation of the inflammasome (1.). Moreover, our findings implicate a colocalisation 
of the inflammasome in secretory vesicles (2.) and tertiary granules (3.) in human 
neutrophils. Considering the function of secretory vesicles, it is conceivable that 
stimulated neutrophils are able to translocate their inflammasomes to the cell surface, 
where they could participate in pathogen recognition and uptake. Since inflammasomal 
components were also found in some granules, a function of the inflammasome in 
phagolysosomes is also feasible. 
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6.6 Perspectives 
Clearly, many future studies are required to dissect the intracellular pathways that 
control the expression, processing, and secretion of the IL-1 family cytokines. Some 
possible further research directions and methodical optimisations are: 
 
• Stimulation experiments with cells isolated from CINCA patients, the most 
severe form of CAPS, could provide clearer results concerning the intrinsic 
inflammasome activation. 
 
• The examination if CIAS1 mutated neutrophils show a down-regulation of 
activating cell surface receptors (LPS/TLR4 or ATP) could deliver interesting 
information about auto-regulatory feed-back loops. 
 
• Possible strategies for a further clarification of the IL-18 expression mode in 
neutrophils: measurements at mRNA level by quantitative real-time polymerase 
chain reaction (RT-PCR) or at protein level by the detection of pro-IL-18 in 
lysed granulocytes. 
 
• The general measurement of LDH in the supernatants could be useful to 
foreclose a role of cell lysis in the externalisation of the cytokines. 
 
• AEBSF (4-(2-Aminoethyl) benzenesulfonyl fluoride hydrochloride), a serine 
protease inhibitor that is stable in aqueous solutions, could be an alternative to 
PMSF, which is an irreversible inhibitor but very unstable in the presence of 
water. 
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7. Conclusions 
• Neutrophils secreted IL-1β and IL-18, but not IL-1α or IL-33. 
 
• Activation of neutrophils’ inflammasome mediated IL-1β secretion, but not IL-1α, 
IL-18 or IL-33 release. 
 
• Nigericin was about 2-fold more potent in triggering IL-1β release by both 
partially and highly purified neutrophils compared to ATP. 
 
• Serine proteases and caspases were partially and differentially involved in the 
neutrophil IL-1ß production, depending on the stimulus. The LPS/nigericin-
induced IL-1β generation seemed to depend stronger on caspases, the LPS/ATP-
induced cytokine secretion was more strongly linked on serine protease activity. 
 
• Inhibitors of caspase-1 are not able to interfere with the whole spectrum of IL-1ß 
production pathways. 
 
• The IL-1β protein production by human neutrophils was substantially affected by 
the cell purity. 
 
• The highly purified neutrophils secreted IL-1β and IL-1α in a substantially lower 
level compared to the PBMCs, whereas they produced nearly twice as much IL-18 
as the autologous PBMCs. 
 
• PBMCs secreted IL-1β, IL-18, and IL-1α in an inflammasome-dependent manner. 
IL-33 that was not detectable in the PBMC cell culture supernatants. 
 
• Neutrophils from MWS patients released lower levels of IL-1β compared to 
healthy control neutrophils after extrinsic inflammasome stimulation. This 
suggests that constitutive intrinsic inflammasome activation limits the exogenous / 
ligand-induced inflammasome responsiveness.  
 
• Production of IL-18 by MWS neutrophils appeared to be inflammasome 
independent and tended to be lower in the CIAS1 mutated neutrophils than in the 
healthy control cells. 
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• ASC and caspase-1 were expressed at protein level by human neutrophils. 
 
• Neutrophils stored NLRP3 inflammasome components in the cytoplasm as well as 
in mobilisable compartments (secretory vesicles and tertiary granules). 
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8. Summary 
The ‘inflammasome’, a multi-protein complex in monocytes and granulocytes, has 
emerged as playing a key role in innate immunity and inflammation. Regarding 
monocytes, definite data are available that the inflammasome, localised in the cytosol, 
controls the maturation of different interleukins via caspase-1 activation. Concerning 
the situation in neutrophil granulocytes—which was the main focus of our research—
little is currently known about the subcellular localisation and the function of the 
inflammasome. To precisely characterise the localisation of the inflammasome in 
neutrophils, we utilised subcellular fractionation and detected inflammasomal 
components not only in the cytoplasm but also in mobile vesicles and granules. These 
findings may implicate that neutrophils are able to regulate their inflammasomes 
dynamically between intracellular stores and the cell surface, where they could 
participate in pathogen recognition and uptake. To gain a better understanding about the 
function of the inflammasomes in neutrophils, we stimulated highly purified cells with 
known inflammasome activators. The results of these experiments suggest that 
inflammasome activation in human neutrophils triggers the IL-1β, but not the IL-18, 
IL-1α, or IL-33 protein secretion. Besides the inflammasome-mediated pathway, IL-1β 
was also produced in an inflammasome-independent fashion through the action of 
serine proteases. IL-18 was already secreted at baseline conditions and we could not see 
a further increase after stimulation. In our experimental conditions, neutrophils were 
unable to release detectable amounts of IL-1α or IL-33. The isolated autologous 
monocytes produced IL-1ß, IL-1α, and IL-18 in an inflammasome-dependent manner, 
whereas IL-33 was not detectable in the cell culture supernatants of the monocytes. 
Methodologically, our studies raised the point that contaminating monocytes have to be 
considered when interpreting IL-1β quantification results from traditional density 
gradient derived neutrophils. To investigate the effect of intrinsic inflammasome 
activation on neutrophils, we studied patients with MWS (Muckle-Wells syndrome), a 
rare disorder characterised by constitutively increased inflammasome activity. The 
neutrophils from patients with MWS showed a tendency towards lower IL-1ß and IL-18 
levels in the stimulation assays compared to healthy control cells. We hypothesised that 
the constitutive intrinsic activation of the inflammasome in MWS patients limits the 
exogenous inflammasome responsiveness. 
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9. Zusammenfassung 
Eine Schlüsselrolle in der unspezifischen Immunantwort spielt das „Inflammasom“, ein 
Multiproteinkomplex in Monozyten und Granulozyten. Hierbei liegen in Bezug auf 
Monozyten eindeutige Daten vor, dass das im Zytosol lokalisierte Inflammasom über 
eine Caspase-1-Aktivierung die Generierung von verschiedenen Interleukinen steuert. 
Im Gegensatz dazu ist im Hinblick auf neutrophile Granulozyten - die im Fokus 
unserer Forschung standen - nur wenig über Funktion und subzelluläre Lokalisation des 
Inflammasoms bekannt. Zur genaueren Lokalisation des Inflammasoms fraktionierten 
wir die subzellulären Bestandteile von Neutrophilen und konnten inflammasomale 
Proteine nicht nur im Zytoplasma, sondern auch in Vesikeln und Granula nachweisen. 
Dies gibt Anlass zur Spekulation, dass Neutrophile mit ihren Inflammasomen flexibel 
zwischen Zelloberfläche und intrazellulären Speichern operieren können. Um ein 
besseres Verständnis über die Funktion der Inflammasomen zu erlangen wurden 
hochaufgereinigte Neutrophile mit bekannten Inflammasomaktivatoren stimuliert. Die 
Ergebnisse dieser Experimente deuten darauf hin, dass das Inflammasom in 
Neutrophilen zwar die Bildung von IL-1ß, aber nicht die von IL 18, IL-1α oder IL-33 
triggert. Neben dem Inflammasom-abhängigen Produktionsweg wurde IL-1ß jedoch 
auch Inflammsom-unabhängig über Serinproteasen aktiviert. IL-18 wurde bereits durch 
unstimulierteNeutrophile sezerniert, ohne weitere Produktionssteigerung nach 
Stimulation. IL-1α und IL-33 konnten beide nicht in den Kulturüberständen der 
Neutrophilen nachgewiesen werden. Die autologen Monozyten produzierten die 
untersuchen Zytokine, mit der Ausnahme des nicht nachweisbaren IL-33, 
Inflammasom-abhängig. Bezüglich der methodischen Verfahrensweise konnten wir 
beim Vergleich von traditionell isolierten Neutrophilen mit speziell hochaufgereinigten 
Zellen zeigen, dass die Aussagekraft von Stimulationsexperimenten mit Neutrophilen in 
hohem Maße von kontaminierenden Monozyten abhängig ist. Um den Effekt von 
intrinsischer Inflammasomenaktivierung auf Neutrophile zu erforschen, untersuchten 
wir Patienten mit MWS (Muckle-Wells-Syndrom), einer seltenen, durch erhöhte 
Inflammasomaktivität gekennzeichnete, Erkrankung. Die MWS Neutrophile 
produzierten nach Stimulation weniger IL-1ß und IL-18 verglichen zu den gesunden 
Zellen. Wir vermuten, dass die in MWS-Patienten vorliegende konstitutive intrinsische 
Aktivierung die Bereitschaft für eine exogene Stimulation des Inflammasoms senkt. 
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10. Appendix 
10.1 Abbreviations 
AEBSF 4-(2-Aminoethyl) benzenesulfonyl fluoride hydrochloride 
ASC apoptosis-associated speck-like protein containing a CARD 
ATP adenosine triphosphate 
bis-tris bis(2-hydroxyethyl)-amino-tris(hydroxymethyl)-methane 
BSA bovine serum albumin  
CANP calcium-activated neutral protease 
CAPS cryopyrin-associated periodic syndrome  
CARD caspase recruitment domain 
CD cluster of differentiation  
CFU-GEMM 
colony forming unit granulocyte, erythrocyte, macrophage, 
megakaryocyte 
CLR C-type lectin receptors 
CO2 carbon dioxide 
cRPMI complete Roswell Park Memorial Institute medium 
DAMP damage-associated molecular pattern 
DNA deoxyribonucleic acid  
DNase deoxyribonuclease 
D-PBS Dulbecco's phosphate buffered saline 
dsDNA double-stranded DNA  
ECL enhanced chemiluminescence 
EGTA ethylene glycol tetraacetic acid  
ELISA enzyme-linked immunosorbent assay  
FACS fluorescence-activated cell sorting  
Fc region fragment crystallisable region  
FCS fetal calf serum 
GP granular protein 
H20 water 
HIN H inversion 
HLA human leukocyte antigen 
HMGB1 high mobility group 1 
HRP horseradish peroxidise 
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IgG immunoglobulin G  
IGIF interferon-gamma inducing factor 
IL-1R IL-1 receptor 
IL-1ß interleukin-1 beta  
LPS lipopolysaccharide 
LRR leucine-rich repeat 
MAMP microbe-associated molecular pattern 
MBL mannan binding lectin 
MES morpholinoethansulphate 
MHC major histocompatibility complex 
MICA MHC class I chain-related molecule A 
MMP-9 matrix metallopeptidase 9  
MPO myeloperoxidase 
MWS Muckle-Wells syndrome 
NACHT NAIP, CIITA, HET-E, TP-1 
NF-κB nuclear factor kappa-light-chain-enhancer of activated B cells  
NGAL neutrophil gelatinase-associated lipocalin 
NK-cell natural killer cell 
NLR NOD-like receptor 
NLRP3 NOD-like receptor family, pyrin domain containing protein 3 
NOD nucleotide-binding oligomerisation domain  
PAMP pathogen-associated molecular pattern 
PBMC peripheral blood mononuclear cell  
PBS-T phosphate buffered saline-Tween 
PIPES Piperazine-1,4-bis(2-ethanesulfonic acid) 
PMN polymorphonuclear leukocyte 
PMSF phenylmethylsulfonyl fluoride  
PRR pattern-recognition receptor 
PVDF polyvinylidenfluorid 
PVP polyvinylpyrrolidone 
RIG retinoic acid-inducible gene 
RPMI Roswell Park Memorial Institute medium  
SDS-PAGE sodium dodecyl sulphate polyacrylamide gel electrophoresis 
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ß2M Beta-2 microglobulin 
TLR Toll-like receptor 
TMB 3,3’,5,5’-tetramethylbenzidine 
TNFα tumor necrosis factor alpha  
WT wild type  
Z-VAD-FMK carbobenzoxy-valyl-alanyl-aspartyl-(O-methyl)-fluoromethylketone 
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